icahn.mssm.edu · 2020. 8. 24. · fogarty international center/nih/dhhs par-19-038 04-nov-2020...

`Grants and Contracts Office

Grants and Contracts Office

Funding Opportunities Monthly Edition November 2020 Due Dates

Introduction

This funding opportunity packet contains information on funding opportunities with deadlines in November 2020. The opportunities are organized in the following order:

1. National Institutes of Health (NIH)2. National Science Foundation (NSF)3. Other Federal4. Non Federal

2

NIH Funding Opportunities

SPIN ID Program Title Sponsor Name Sponsor Number Deadline Date Funding

Amount

NIH Funding Opportunities Due: Nov 2020

078192 Emerging Global Leader Award (K43) Fogarty International Center/NIH/DHHS PAR-19-038 04-Nov-2020 525,000

USD

Contact Name Christine Jessup, Ph.D Contact Telephone 301-496-1653

Contact Email [email protected] Sponsor Website

Program URL Link to program URL Deadline Dates (ALL) 04-Nov-2020

Synopsis

This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA PAR-17-001. The purpose of the Fogarty Emerging Global Leader Award is to provide research support and protected time (three to five years) to an early career research scientist from a low- or middle-income country (LMIC) who holds a junior faculty position at an LMIC academic or research institution, as defined by the World Bank (http://data.worldbank.org/about/country-classifications/country-and-lending-groups , including “low-income,” “lower-middle-income,” and “upper-middle-income” countries). This intensive, mentored research career development experience is expected to lead to an independently funded research career at the LMIC institution or in another LMIC. This Funding Opportunity Announcement (FOA) invites applications from LMIC scientists from any health-related discipline who propose career development activities and a research project that is relevant to the health priorities of their country under the mentorship of LMIC and U.S. mentors.

075754 Global Brain and Nervous System Disorders Research Across the Lifespan (R01 Clinical Trials Optional)

Fogarty International Center/NIH/DHHS PAR-18-835 06-Nov-2020 Not

Specified

Contact Name Kathleen Michaels, Ph.D., Program Director Contact Telephone 301-496-1653



Synopsis National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for the conduct of

3

https://spin.infoedglobal.com/Program.html?078192

mailto:[email protected]

https://grants.nih.gov/grants/guide/pa-files/PAR-19-038.html







Amount


innovative, collaborative research projects between U.S. and low- and middle-income country (LMIC) scientists, on brain and other nervous system function and disorders throughout life, relevant to LMICs (including neurological, mental, behavioral, alcohol and substance use disorders and spanning the full range of science from basic to implementation research). Scientists in upper middle-income LMICs (UMICs) are also eligible to partner directly with scientists at other LMIC institutions with or without out a US partner. Income categories are defined by the World Bank at http://data.worldbank.org/about/country-classifications/country-and-lending-groups. The collaborative research programs are expected to contribute to the long-term goals of building and strengthening sustainable research capacity in LMICs to address nervous system development, function and impairment throughout life and to lead to diagnostics, prevention, treatment and implementation strategies. The proposed work will also contribute to developing a base for research networking and evidence-based policy beyond the specific research project. This program will use the NIH Research Project (R01) award mechanism.

078365 Emerging Global Leader Award (K43 Independent Clinical Trial Required)

Fogarty International Center/NIH/DHHS PAR-19-051 04-Nov-2020 525,000

USD




Synopsis

This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA PAR-17-001. The purpose of the Fogarty Emerging Global Leader Award is to provide research support and protected time (three to five years) to an early career research scientist from a low- or middle-income country (LMIC) who holds a junior faculty position at an LMIC academic or research institution, as defined by the World Bank (http://data.worldbank.org/about/country-classifications/country-and-lending-groups , including “low-income,” “lower-middle-income,” and “upper-middle-income” countries). This intensive, mentored research career development experience is expected to lead to an independently funded research career at the LMIC institution or in another LMIC. This Funding Opportunity Announcement (FOA) invites applications from LMIC scientists from any health-related discipline who propose career development activities and a research project that is relevant to the health priorities of their country under the mentorship of LMIC and U.S. mentors.

4







Amount


075755 Global Brain and Nervous System Disorders Research Across the Lifespan (R21 Clinical Trial Optional)


USD

Contact Name Kathleen Michaels, Ph.D., Program Director Contact Telephone 301-496-1653



Synopsis

National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for the conduct of innovative, collaborative research projects between U.S. and low- and middle-income country (LMIC) scientists, on brain and other nervous system function and disorders throughout life, relevant to LMICs (including neurological, mental, behavioral, alcohol and substance use disorders and spanning the full range of science from basic to implementation research). Scientists in upper middle-income LMICs (UMICs) are also eligible to partner directly with scientists at other LMIC institutions with or without out a US partner. Income categories are defined by the World Bank at http://data.worldbank.org/about/country-classifications/country-and-lending-groups. The collaborative research programs are expected to contribute to the long-term goals of building and strengthening sustainable research capacity in LMICs to address nervous system development, function and impairment throughout life and to lead to diagnostics, prevention, treatment and implementation strategies. The proposed work will also contribute to developing a base for research networking and evidence-based policy beyond the specific research project. This program will use the NIH R21 Exploratory/Developmental Research Grant award mechanism.

097362 RFA-RM-20-015 -- Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa) Research Hubs (U54–Clinical Trial Optional)

Fogarty International Center/NIH/DHHS RFA-RM-20-015

09-Nov-2020 [Optional][LOI/Pre-App]

6,500,000 USD

Contact Name Brad Newsome, Ph.D. Contact Telephone 301-480-8389


Program URL Link to program URL Deadline Dates (ALL) 09-Nov-2020 [Optional][LOI/Pre-App], 08-Dec-2020 , 08-Feb-2021

Synopsis This Funding Opportunity Announcement (FOA) seeks applications for Research Hubs as part of a broader initiative

5









https://grants.nih.gov/grants/guide/rfa-files/RFA-RM-20-015.html



Amount


entitled Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa). The goal of DS-I Africa is to spur new health discoveries and catalyze innovation in healthcare, public health, and health research on the continent through application of data science. DS-I Africa Research Hubs will be funded to advance data science health research and innovation in Africa and support new African and global partnerships that enhance the impact of data science health research. Hubs will engage government, industry, or other organizations, including diverse departments from academic institutions, that can partner to provide synergistic expertise, collaborate on research, and support data science linked to new technologies and solutions. Applicants must propose at least 2 distinct research projects and a system for soliciting, evaluating, and awarding smaller pilots projects, all focused on a central health theme that addresses priorities in an African country or region. Applications must be submitted from African academic or other non-profit organizations. Proposed partnerships with organizations outside the applicant institution are required and can include all types of organizations in Africa, the U.S., or other countries.

097371 RFA-RM-20-016 -- Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa) Research Training Program (U2RClinical Trial Optional)

Fogarty International Center/NIH/DHHS RFA-RM-20-016

23-Oct-2020 [Optional][LOI/Pre-App]

1,750,000 USD

Contact Name Laura Povlich, Ph.D. Contact Telephone 301-827-2227


Program URL Link to program URL Deadline Dates (ALL) 23-Oct-2020 [Optional][LOI/Pre-App], 24-Nov-2020

Synopsis

This Funding Opportunity Announcement (FOA) seeks applications for Research Training Programs as part of a broader initiative entitled Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa). The goal of DS-I Africa is to spur new health discoveries and catalyze innovation in healthcare, public health, and health research on the continent through application of data science. Through this FOA, DS-I Africa aims to increase capacity to carry out data science health research and innovation in Africa through the support of at least 4 institutional research training cooperative agreement awards. Applicants should propose long-term data science health research training through graduate degree (master's and/or doctoral) training and faculty development. Grantees will train cohorts of African investigators who will have the skills to become independent investigators, research leaders, and research collaborators. The cooperative agreements can either be direct awards to African institutions or awards to U.S. institutions in partnership with African institutions. Regardless of the applicant organization, the training programs must focus on building institutional capacity at one or more African institutions and train African researchers. Partnerships with additional organizations, including for-profit or governmental organizations,

6








Amount


are encouraged as a means to provide applied research experiences for the trainees. This Funding Opportunity Announcement (FOA) allows appointment of Trainees proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

084554 Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle-Income Countries (R21 Clinical Trial Optional)


USD

Contact Name Geetha P. Bansal, Ph.D. Contact Telephone 301-496-1492



Synopsis

The purpose of this FOA is to stimulate research on interventions to reduce HIV/AIDS-associated stigma and its impact on the prevention and treatment of HIV/AIDS and on the quality of life of People Living with HIV/AIDS (PLWH). Specifically, this initiative will support intervention research on a) novel stigma reduction strategies that link to increase in care-seeking behavior and/or decrease in transmission, b) reducing the impact of stigma on adolescent and/or youth health, c) strategies to cope with the complex burden of stigmatization due to HIV and one or more comorbidities/coinfections, d) reducing the effects of stigma on, and/or by, family members or caregivers of PLWH and e) development of innovative and improved stigma measurement in the context of implementation of a stigma-reduction intervention. The overall goals are to understand how to reduce stigma as a factor in HIV transmission, to eliminate or mitigate the aspects of stigma that limit beneficial health outcomes for the infected and at-risk individuals and communities, and to conduct exploratory studies to determine the feasibility of stigma-reduction interventions related to HIV prevention, treatment and/or care in Low and Middle-Income Countries (LMICs).

079025 Emerging Global Leader Award (K43 Independent Clinical Trial Not Allowed)


USD


Contact Email [email protected]

7











Amount


Sponsor Website Program URL Link to program URL

Deadline Dates (ALL) 04-Nov-2020

Synopsis

This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary study to a clinical trial. Applicants to this FOA are permitted to propose research experience in a clinical trial led by a mentor or co-mentor. Applicants proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion FOA PAR-19-051. The purpose of the Fogarty Emerging Global Leader Award is to provide research support and protected time (three to five years) to an early career research scientist from a low- or middle-income country (LMIC) who holds a junior faculty position at an LMIC academic or research institution, as defined by the World Bank (http://data.worldbank.org/about/country-classifications/country-and-lending-groups , including “low-income,” “lower-middle-income,” and “upper-middle-income” countries). This intensive, mentored research career development experience is expected to lead to an independently funded research career at the LMIC institution or in another LMIC. This Funding Opportunity Announcement (FOA) invites applications from LMIC scientists from any health-related discipline who propose career development activities and a research project that is relevant to the health priorities of their country under the mentorship of LMIC and U.S. mentors.

092676 New Informatics Tools and Methods to Enhance U.S. Cancer Surveillance Research (U01 Clinical Trial Optional)

National Cancer Institute/NIH/DHHS PAR-20-170 18-Nov-2020 Not

Specified

Contact Name Angela B. Mariotto, PhD Contact Telephone 240-276-6698


Program URL Link to program URL Deadline Dates (ALL) 18-Nov-2020 , 06-Jun-2021 , 18-Nov-2021 , 06-Jun-2022 , 18-Nov-2022 , 06-Jun-2023

Synopsis

The goal of this Funding Opportunity Announcement (FOA) is to advance surveillance science by supporting the development of new and innovative tools and methods for more efficient, detailed, timely, and accurate data collection by cancer registries. Specifically, the FOA solicits applications for projects to develop, adapt, apply, scale-up, and validate tools and methods to improve the collection and integration of cancer registry data to expand the data items collected. Applications proposed must be based on partnership with at a minimum of two U.S. population-based central cancer registries. Tools and methods proposed for development are expected to enhance the registry core infrastructure and, in so doing, expand the usefulness of registry-collected data to support high-quality cancer research. The scientific scope of this FOA includes but is

8








Amount


not limited to Development, validation, evaluation of scalable tools/methods to facilitate automatic/unsupervised extraction and cosolidation of specific data from various types of unstructured medical records as for example, pathology reports, diagnostic imaging, laboratory, hospital discharge forms and clinical visits; Supplementation of cancer registries with new or more detailed data items, from existing data sources or from linkages with novel data sources, e.g. electronic medical records (EMR) Funds will be made available through the U01 cooperative agreement award mechanism.

089582 Toward Translation of Nanotechnology Cancer Interventions (TTNCI) (R01 Clinical Trial Not Allowed)

National Cancer Institute/NIH/DHHS PAR-20-116 19-Nov-2020 1,900,000

USD

Contact Name Piotr Grodzinski, Ph.D. Contact Telephone 240-781-3305


Program URL Link to program URL Deadline Dates (ALL) 19-Nov-2020 , 20-May-2021 , 18-Nov-2021

Synopsis

This Funding Opportunity Announcement (FOA), entitled "Toward Translation of Cancer Nanotechnology Interventions (TTNCI)" is to enable the translation of nanotechnology-based cancer interventions relying on next-generation nanoparticle formulations and/or nano-devices. The TTNCI initiative encourages applications for advanced pre-clinical research, supporting translation of nanotechnology-based cancer diagnostics and therapeutics. The "Toward Translation of Nanotechnology Cancer Interventions" (TTNCI) awards are designed to mature experimental nanomedicines relying on "next-generation" nanoparticles and nano-devices which demonstrate strong potential to improve treatment effectiveness and/or tackle cancers that currently have a very limited arsenal of approved therapies or diagnostic strategies. TTNCI awards are expected to enable further development of proposed nanotechnology-based interventions to the stage in which they could continue on a developmental path towards the NCI Experimental Therapeutics (NExT) and other NCI translational programs.

088331 RFA-CA-20-005 -- Research Answers to National Cancer Institute's (NCI) Provocative Questions (R21 Clinical Trial Optional)

National Cancer Institute/NIH/DHHS RFA-CA-20-005


275,000 USD

Contact Name Sean E. Hanlon, Ph.D. Contact Telephone 240-781-3310


9










Amount



Synopsis

The purpose of this Funding Opportunity Announcement (FOA) is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute (NCI) Provocative Questions Initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention. Some of these "Provocative Questions" (PQs) stem from intriguing but older, neglected observations that have never been adequately explored. Other PQs are built on more recent findings that are perplexing or paradoxical, revealing important gaps in current knowledge. Finally, some PQs reflect problems that traditionally have been thought to be intractable but that now may be open to investigations using new strategies and recent technical advances. The current issuance of the PQ Initiative includes an updated set of 9 PQs. Each research project proposed in response to this FOA must be focused on addressing the research problems defined by a specific PQ selected from the list. Projects proposed to address PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged if they serve the scientific focus of the selected PQ.

088350 RFA-CA-20-004 -- Research Answers to National Cancer Institute's (NCI) Provocative Questions (R01 Clinical Trial Optional)



Not Specified

Contact Name Sean E. Hanlon, Ph.D. Contact Telephone 240-781-3310



Synopsis

The purpose of this Funding Opportunity Announcement (FOA) is to support research projects designed to solve specific problems and paradoxes in cancer research identified by the National Cancer Institute (NCI) Provocative Questions Initiative. These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in cancer research. Rather, they are meant to challenge researchers to think about and elucidate specific problems in key areas of cancer research that are deemed important but have not received sufficient attention. Some of these "Provocative Questions" (PQs) stem from intriguing but older, neglected observations that have never been adequately explored. Other

10

https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-20-005.html







Amount


PQs are built on more recent findings that are perplexing or paradoxical, revealing important gaps in current knowledge. Finally, some PQs reflect problems that traditionally have been thought to be intractable but that now may be open to investigations using new strategies and recent technical advances. The current issuance of the PQ Initiative includes an updated set of 9 PQs. Each research project proposed in response to this FOA must be focused on addressing the research problems defined by a specific PQ selected from the list. Projects proposed to address PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged if they serve the scientific focus of the selected PQ.

076438 Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)


USD

Contact Name Scott Rogers, MPH Contact Telephone 240-276-6932


Program URL Link to program URL Deadline Dates (ALL) 06-Nov-2020 , 08-Mar-2021

Synopsis

National Cancer Institute (NCI) invites applications for research in cancer control and population sciences. The overarching goal is to provide support to promote research efforts on novel scientific ideas that have the potential to substantially advance cancer research in statistical and analytic methods, epidemiology, cancer survivorship, cancer-related behaviors and behavioral interventions, health care delivery, and implementation science. This FOA will use the NIH Research Project (R01) award mechanism.

096374 3D Technologies to Accelerate HTAN Atlas Building Efforts (UH2 Clinical Trial Not Allowed)



500,000 USD

Contact Name Philipp Oberdoerffer, Ph.D. Contact Telephone 240-760-6681



11











Amount


Synopsis

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) as a part of its Beau Biden Cancer Moonshot Initiative invites submission of applications requesting support for projects that will accelerate cancer research. Specifically, this FOA targets the following area designated as a scientific priority by the Blue Ribbon Panel (BRP) as Recommendation I: Generation of Human Tumor Atlases.

082323 Provocative Questions (PQs) in Multiple Myeloma Disparities Research (R21 Clinical Trial Optional)

National Cancer Institute/NIH/DHHS PAR-19-280 15-Nov-2020 275,000

USD

Contact Name Amy Kennedy, Ph.D., M.P.H. Contact Telephone 240-781-3335



Synopsis

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites R21 applications for exploratory/developmental research projects designed to solve specific problems and paradoxes in multiple myeloma (MM) and disparities research identified as the NCI Multiple Myeloma Disparities Provocative Questions (MMD PQs). These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in multiple myeloma research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of multiple myeloma and disparities research that are deemed important but have not received sufficient attention. The FOA includes six Multiple Myeloma PQs that represent diverse fields relevant to multiple myeloma disparities research, but all are framed to inspire interested scientists to conceive new approaches and/or feasible solutions. Each research project (application) proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific MMD PQ selected from the list. Projects proposed to address specific MMD PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen.

082322 Provocative Questions (PQs) in Multiple Myeloma Disparities Research (R01 Clinical Trial Optional)


Specified

Contact Name Amy Kennedy, Ph.D., M.P.H. Contact Telephone 240-781-3335


12










Amount




Synopsis

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) invites R01 applications for research projects designed to solve specific problems and paradoxes in multiple myeloma (MM) and disparities research identified as the NCI Multiple Myeloma Disparities Provocative Questions (MMD PQs). These problems and paradoxes phrased as questions are not intended to represent the full range of NCI's priorities in multiple myeloma research. Rather, they are meant to challenge cancer researchers to think about and elucidate specific problems in key areas of multiple myeloma and disparities research that are deemed important but have not received sufficient attention. The FOA includes six Multiple Myeloma PQs that represent diverse fields relevant to multiple myeloma disparities research, but all are framed to inspire interested scientists to conceive new approaches and/or feasible solutions. Each research project (application) proposed in response to this FOA must be focused on addressing one particular research problem defined by one specific MMD PQ selected from the list. Projects proposed to address specific MMD PQs may use strategies that incorporate ideas and approaches from multiple disciplines, as appropriate. Transdisciplinary projects are encouraged as long as they serve the scientific focus of the specific PQ chosen.

088443 RFA-CA-20-007 -- Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)



275,000 USD

Contact Name Juli Klemm, Ph.D. Contact Telephone 301-480-5778



Synopsis

The purpose of this Funding Opportunity Announcement (FOA) is to invite exploratory/developmental research grant applications (R21) for the development of innovative methods and algorithms in biomedical computing, informatics, and data science addressing priority needs across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA encourages applications focused on the development of novel computational, mathematical, and statistical algorithms and methods that

13









Amount


can considerably improve acquisition, management, analysis, and dissemination of relevant data and/or knowledge. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, there must be a clear rationale for how the proposed informatics method or algorithm is novel and how it will benefit the cancer research field. Potential applicants who are interested in downstream technology development, from prototyping to hardening and adaptation, should consult the other companion FOAs.

080277 Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer (R21 Clinical Trial Not Allowed)


USD

Contact Name Young S. Kim, PhD Contact Telephone 240-276-7115


Program URL Link to program URL Deadline Dates (ALL) 06-Nov-2020 , 10-Jun-2021 , 08-Nov-2021

Synopsis

The purpose of this Funding Opportunity Announcement (FOA) is to support research which can elucidate mechanism(s) of action by which gut microbes inhibit or enhance anti-tumor immune responses. Thus, research projects should be focused on delineating how specific microbes or their metabolites target host immune responses to prevent colitis-associated or sporadic tumor formation.

080274 Modulating Intestinal Microbiota to Enhance Protective Immune Responses against Cancer (R01 Clinical Trial Not Allowed)


Specified

Contact Name Young S. Kim, PhD Contact Telephone 240-276-7115



Synopsis The purpose of this Funding Opportunity Announcement (FOA) is to support research which can elucidate mechanism(s) of action by which gut microbes inhibit or enhance anti-tumor immune responses. Thus, research projects should be focused

14











Amount


on delineating how specific microbes or their metabolites target host immune responses to prevent colitis-associated or sporadic tumor formation.

088454 RFA-CA-20-010 -- Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)



Not Specified




Synopsis

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for the continued development and sustainment of high value informatics research resources to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on sustaining operations and improving the user experience and availability of existing, widely-adopted informatics tools and resources. This is in contrast to early-stage and advanced development efforts to generate these tools and resources that are supported by companion ITCR FOAs. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, the proposed sustainment plan must provide clear justification for why the research resource should be maintained and how it has benefitted and will continue to benefit the cancer research field. In addition, mechanisms for assessing and maximizing the value of the resource to researchers and supporting collaboration and deep engagement between the resource and the targeted research community should be described.

088452 RFA-CA-20-009 -- Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)



3,000,000 USD


15









Amount




Synopsis

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U24) applications for advanced development and enhancement of emerging informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on emerging informatics technology, defined as one that has passed the initial prototyping and pilot development stage, has demonstrated potential to have a significant and broader impact, has compelling reasons for further improvement and enhancement, and has not been widely adopted in the cancer research field. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included. Potential applicants who are interested in early-stage development or informatics resource sustainment should consult the companion FOAs listed above.

088448 RFA-CA-20-008 -- Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)



900,000 USD




Synopsis

The purpose of this Funding Opportunity Announcement (FOA) is to invite Cooperative Agreement (U01) applications for the development of enabling informatics technologies to improve the acquisition, management, analysis, and dissemination of data and knowledge across the cancer research continuum including cancer biology, cancer treatment and diagnosis, early cancer detection, risk assessment and prevention, cancer control and epidemiology, and/or cancer health disparities. As a

16










Amount


component of the NCI's Informatics Technology for Cancer Research (ITCR) Program, this FOA focuses on early-stage development from prototyping to hardening and adaptation. Early-stage development is defined for the purpose of this FOA as initial tool development or the significant modification of existing tools for new applications. The central mission of ITCR is to promote research-driven informatics technology across the development lifecycle to address priority needs in cancer research. In order to be successful, proposed development plans must have a clear rationale on why the proposed technology is needed and how it will benefit the cancer research field. In addition, mechanisms to solicit feedback from users and collaborators throughout the development process must be included.

088464 RFA-CA-20-013 -- Revision Applications to Support the Application of Informatics Technology for Cancer Research (U24 Clinical Trial Optional)



200,000 USD




Synopsis

The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U24 resource-related research projects. These revision applications can request support for expansion of the original scope of the parent study by incorporating informatics methods, tools or resources developed through current or previous support from the NCI Informatics Technology for Cancer Research (ITCR) Program. Awards from this FOA are meant to spur novel collaborations and to incentivize the adoption, adaptation, and integration of these informatics technologies in support of the appropriate research communities. As a component of the NCI ITCR program, this FOA aims to promote interdisciplinary collaboration in the adoption and enhancement of innovative informatics methods, tools, and resources that enable cancer research and accelerate scientific discovery.

088463 RFA-CA-20-012 -- Revision Applications to Support the Application of Informatics Technology for Cancer Research (U01 Clinical Trials Optional)



200,000 USD


17











Amount




Synopsis

The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI U01 research projects. These revision applications can request support for expansion of the original scope of the parent study by incorporating informatics methods, tools or resources developed through current or previous support from the NCI Informatics Technology for Cancer Research (ITCR) Program. Awards from this FOA are meant to spur novel collaborations and to incentivize the adoption, adaptation, and integration of these informatics technologies in support of the appropriate research communities. As a component of the NCI ITCR program, this FOA aims to promote interdisciplinary collaboration in the adoption and enhancement of innovative informatics methods, tools, and resources that enable cancer research and accelerate scientific discovery.

088457 RFA-CA-20-011 -- Revision Applications to Support the Application of Informatics Technology for Cancer Research (R01 Clinical Trials Optional)



200,000 USD




Synopsis

The purpose of this Funding Opportunity Announcement (FOA) is to encourage revision applications (formerly called "competing revisions") from currently funded NCI R01 research projects. These revision applications can request support for expansion of the original scope of the parent study by incorporating informatics methods, tools or resources developed through current or previous support from the NCI Informatics Technology for Cancer Research (ITCR) Program. Awards from this FOA are meant to spur novel collaborations and to incentivize the adoption, adaptation, and integration of these informatics technologies in support of the appropriate research communities. As a component of the NCI ITCR program, this FOA aims to promote interdisciplinary collaboration in the adoption and enhancement of innovative informatics methods, tools, and resources that enable cancer research and accelerate scientific discovery.

18










Amount


081438 Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention (R21 Clinical Trial Optional)


USD

Contact Name Wendy Wang, Ph.D. M.Sc. Contact Telephone 240-276-7117


Program URL Link to program URL Deadline Dates (ALL) 06-Nov-2020 , 08-Jul-2021 , 08-Nov-2021

Synopsis

The overall objective of this Funding Opportunity Announcement (FOA) is to support innovative research on adducts to cellular macromolecules as indicators of exposures to endogenous and exogenous cancer risk factors relevant to exposures in human populations. The priority is on projects that will focus on adductomic approaches, i.e., address some aspects of the totality of adducts. The ultimate goal is to discover and characterize the utility of adductomic-based exposure indicators for cancer detection, cancer prevention, and/or assessing cancer risks. In well-justified cases, innovative studies using the adductomic approaches in the context of cancer etiology and/or gene-environment interaction research may also be appropriate. For projects intended for NIEHS support, the focus may be on innovative technology and method development.

081437 Basic and Translational Research on Adducts in Cancer Risk Identification and Prevention (R01 Clinical Trial Optional)


Specified

Contact Name Wendy Wang, Ph.D. M.Sc. Contact Telephone 240-276-7117



Synopsis

The overall objective of this Funding Opportunity Announcement (FOA) is to support innovative research on adducts to cellular macromolecules as indicators of exposures to endogenous and exogenous cancer risk factors relevant to exposures in human populations. The priority is on projects that will focus on adductomic approaches, i.e., address some aspects of the totality of adducts. The ultimate goal is to discover and characterize the utility of adductomic-based exposure indicators for cancer detection, cancer prevention, and/or assessing cancer risks. In well-justified cases, innovative studies using the

19











Amount


adductomic approaches in the context of cancer etiology and/or gene-environment interaction research may also be appropriate. For projects intended for NIEHS support, the focus may be on innovative technology and method development.

082789 Research Projects in Cancer Systems Biology (U01 Clinical Trial Optional)


USD

Contact Name Dr. Shannon K. Hughes Contact Telephone 240-276-6224



Synopsis

The National Cancer Institute’s (NCI) Cancer Systems Biology Consortium (CSBC) supports systems biology approaches to cancer research and includes U54 CSBC Research Centers, a U24 CSBC Coordinating Center and, through this FOA, well-defined, discrete and circumscribed U01 Research Projects. CSBC Research Projects are expected to involve interdisciplinary teams of scientists, engineers, and cancer researchers who collaborate to advance our understanding of the mechanisms underlying cancer initiation, progression, and treatment. CSBC Research Projects proposed in response to this Funding Opportunity Announcement must be based upon explicit integration of experimental biology and computational modeling to test and validate novel hypotheses in cancer research.

077749 Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)


USD

Contact Name Abhi Rao, Ph.D. Contact Telephone 240-276-5715


Program URL Link to program URL Deadline Dates (ALL) 09-Nov-2020 , 15-Mar-2021 , 11-Jul-2021

Synopsis This Funding Opportunity Announcement (FOA) will support extramural research to investigate and mitigate challenges facing clinical assay development and subsequent analytical validation due to preanalytical variability in tumor tissue biopsies, blood biospecimens utilized as “liquid biopsies, or other biospecimens as described in this FOA. Extramural research

20











Amount


funded under this FOA may include investigations of preanalytical variability associated with the procurement and study of small biopsies (core biopsies, small excision samples), blood utilized for liquid biopsies, tissue swabs, tissue secretions, pleural and esophageal aspirates, feces, or bodily fluids like sweat, urine, CSF, breast milk and saliva. Investigator-designed experiments will explore how different biospecimen preanalytical conditions affect emerging and clinically relevant biomarkers quantified by a variety of testing platforms. The results from this research program will improve the understanding of how analytical quantification of clinically relevant biomarkers is affected by variation in biospecimen collection, processing, and storage procedures. The overall goal is to expedite biomarker clinical assay development through evidence-based standardization of biopsy handling practices.

072031 Exploratory/Developmental Grants Program for Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)


USD

Contact Name Jennifer Isaacs, Ph.D. Contact Telephone 240-276-6251


Program URL Link to program URL Deadline Dates (ALL) 19-Nov-2020 , 18-Feb-2021

Synopsis

National Cancer Institute (NCI) invites applicationsfrom investigators interested in conducting basic research studies into the biological/genetic causes and mechanisms of cancer health disparities. These awards will support pilot and feasibility studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models and methods that are necessary to conduct basic research in cancer health disparities. In addition, the FOA will further the development of scientific areas, providing support for early-stage exploratory projects that lead to future in-depth mechanistic studies (such as R01 projects) of the biology of cancer health disparities. This FOA will use the NIH R21 Exploratory/Developmental Research award mechanism.

072029 Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)


Specified

Contact Name Jennifer Isaacs, Ph.D. Contact Telephone 240-276-6251

21









Amount




Synopsis

National Cancer Institute (NCI) invites applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention strategies, (2) the development and testing of new methodologies and models, and (3) secondary data analyses. This FOA is also designed to aid and facilitate the growth of a nationwide cohort of scientists with a high level of basic research expertise in cancer health disparities research who can expand available resources and tools, such as biospecimens, patient derived models, and methods that are necessary to conduct basic research in cancer health disparities. This FOA will use the NIH Research Project (R01) award mechanism.

085349 Small Cell Lung Cancer (SCLC) Consortium: Biology, Therapy and Resistance (U01 Clinical Trial Not Allowed)


USD

Contact Name Suzanne Forry, PhD Contact Telephone 240-276-5922


Program URL Link to program URL Deadline Dates (ALL) 12-Nov-2020 , 11-Mar-2021 , 12-Nov-2021 , 11-Mar-2022

Synopsis

This Funding Opportunity Announcement (FOA) invites applications for research projects to join the Small-Cell Lung Cancer (SCLC) Consortium. Goals of the SCLC Consortium pertinent to this FOA are: 1) to learn the mechanistic and biological underpinnings of SCLC formation, progression and heterogeneity; 2) to investigate how molecular vulnerabilities could be used to develop targeted agents or combinations; and 3) to understand clinical resistance to drug and radiation therapy and its rapid development.

097280 NCI Outstanding Investigator Award (R35 Clinical Trial Not Allowed) National Cancer Institute/NIH/DHHS PAR-20-278


4,200,000 USD

22










Amount


Contact Name Christine Siemon Contact Telephone 240-276-6266



Synopsis

This Funding Opportunity Announcement (FOA) invites grant applications for the Outstanding Investigator Award (R35) in any area of cancer research. The objective of the National Cancer Institute (NCI) Outstanding Investigator Award (OIA) is to provide long-term support to accomplished investigators with outstanding records of cancer research productivity who propose to conduct exceptional research. The OIA is intended to allow investigators the opportunity to take greater risks, be more adventurous in their lines of inquiry, or take the time to develop new techniques. The OIA would allow an Institution to submit applications nominating established Program Directors/Principal Investigators (PDs/PIs) for the NCI OIA. It is expected that the OIA would provide extended funding stability and encourage investigators to embark on projects of unusual potential in cancer research. The research projects should break new ground or extend previous discoveries toward new directions or applications that may lead to a breakthrough that will advance biomedical, behavioral, or clinical cancer research.

097710 Core Infrastructure Support for Cancer Epidemiology Cohorts (U01 Clinical Trial Not Allowed)


Specified

Contact Name Joanne Elena, Ph.D., M.P.H. Contact Telephone 240-276-6818


Program URL Link to program URL Deadline Dates (ALL) 12-Nov-2020 , 09-Apr-2021 , 09-Nov-2021 , 07-Apr-2022 , 09-Nov-2022

Synopsis

Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) encourages grant applications for support of the core functions of Cancer Epidemiology Cohorts (CECs), as well as methodological research. This FOA is intended to support the maintenance of existing CECs infrastructure and resource sharing with broader scientific communities.

075883 Oncology Co-Clinical Imaging Research Resources to Encourage National Cancer PAR-18-841 17-Nov-2020 2,500,000

23










Amount


Consensus on Quantitative Imaging Methods and Precision Medicine (U24 - Clinical Trial Optional)

Institute/NIH/DHHS USD

Contact Name Huiming Zhang, Ph.D. Contact Telephone 240-276-5979


Program URL Link to program URL Deadline Dates (ALL) 17-Nov-2020 , 14-Jun-2021

Synopsis

National Cancer Institute (NCI) invites applications to develop research resources that will encourage a consensus on how Quantitative Imaging (QI) methods are optimized to improve the quality of imaging results for co-clinical trials. The scientific goals of this FOA are to: (a) perform the appropriate optimization of the pre-clinical quantitative imaging methods, (b) implement the optimized methods in the co-clinical trial, and finally (c) populate a web-accessible research resource with all the data, methods, workflow documentation, and results collected from the co-clinical investigations. Co-clinical trials are defined in this FOA as investigations in patients and in parallel (or sequentially) in mouse or human-in-mouse models of cancer that mirror the genetics and biology of the patients' malignancies or pre-cancerous lesions. The co-clinical trial should include either (a) a therapeutic goal, such as the prediction, staging, and/or measurement of tumor response to therapies, or (b) a screening and early detection or a cancer risk stratification goal for lethal cancer versus non-lethal disease. Applicants are encouraged to organize multi-disciplinary teams with experience in mouse models research, human investigations, imaging platforms, QI methods, decision support software and informatics to populate the research resource. This FOA will use the NIH U24 Resource-Related Research Projects – Cooperative Agreements award mechanism.

098060 RFA-CA-20-052 -- Limited Competition: Childhood Cancer Survivor Study (U24 Clinical Trial Required)



13,711,185 USD

Contact Name Nita L. Seibel, MD Contact Telephone 240-276-6078



24











Amount


Synopsis

The purpose of this limited competition Funding Opportunity Announcement (FOA) is to continue support for the Childhood Cancer Survivor Study (CCSS) as a resource enabling broad studies on the long-term effects of cancer and its associated therapies on survivors of pediatric and adolescent cancers. CCSS is a multi-institutional collaborative project that supports a participant cohort of over 25,000 five-year survivors of childhood cancer diagnosed between 1970-1999 and over 5,000 sibling control subjects.

098054 Innovative Research in Cancer Nanotechnology (IRCN) (R01 Clinical Trial Not Allowed)


USD

Contact Name Piotr Grodzinski, Ph.D. Contact Telephone 240-781-3305


Program URL Link to program URL Deadline Dates (ALL) 04-Nov-2020 , 06-May-2021 , 04-Nov-2021 , 05-May-2022 , 03-Nov-2022 , 04-May-2023

Synopsis

This Funding Opportunity Announcement (FOA) entitled "Innovative Research in Cancer Nanotechnology (IRCN)" encourages applications promoting transformative discoveries in cancer biology and/or oncology through the use of nanotechnology. Proposed projects should address major barriers in cancer biology and/or oncology using nanotechnology and should focus on mechanistic studies to expand the fundamental understanding of nanomaterial and/or nano-device interactions with biological systems. These studies are expected to be relevant to the delivery of nanoparticles and/or nano-devices to desired and intended cancer targets in vivo and/or characterization of detection and diagnostic devices and sensors in vitro. IRCN awards are expected to produce fundamental knowledge to aid future and more informed development of nanotechnology-based cancer interventions.

069919 Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required)

National Center for Complementary and Integrative Health/NIH/DHHS

PAR-18-417 07-Sep-2020 450,000 USD

Contact Name Lanay M. Mudd, Ph.D. Contact Telephone 301-594-9346


Program URL Link to program URL

25











Amount


Deadline Dates (ALL) 07-Sep-2020 , 16-Oct-2020 , 16-Nov-2020 , 07-Jan-2021

Synopsis

National Center for Complementary and Integrative Health (NCCIH) invites applications for early phase clinical trials of mind and body approaches for conditions that have been identified by NCCIH as high priority research topics. This funding opportunity is intended to support feasibility clinical trials, which will provide data that are critical for the planning and design of a subsequent controlled cohort study, clinical efficacy or effectiveness study, or a pragmatic trial. The data collected should be used to fill gaps in scientific knowledge necessary to develop a competitive full-scale clinical trial, including, but not limited to the following: adapting an intervention to a specific population; refining the intervention to determine the most appropriate frequency or duration; determining feasibility of recruitment, retention and data collection procedures; examining acceptability of the intervention and control conditions. This FOA will not support randomized clinical trials to test or determine efficacy or effectiveness. Applications that propose solely to write a protocol or manual of operations or to develop infrastructure for a clinical trial are not appropriate for this announcement. The subsequent larger trial should have the potential to make a significant impact on public health. This FOA will use the NIH R34 Planning Grant award mechanism.

077294 U.S. - India Collaborative Vision Research Program (R01 Clinical Trial Not Allowed) National Eye Institute/NIH/DHHS PAR-18-912 09-Nov-2020 750,000

USD

Contact Name Lisa Neuhold, Ph.D. Contact Telephone 301-451-2020



Synopsis

National Eye Institute (NEI) invites applications from Multiple Principal Investigator (Multi-PD/PI) applications from United States (U.S.)-based institutions with an Indian institution partner to establish bilateral collaborations that will advance science and technology important to understanding, preventing, and treating blinding eye diseases, visual disorders, and their complications. Applications are encouraged from organizations/institutions that propose to conduct research on the basic biology and/or genetics of ophthalmic diseases through collaborations with Indian investigators on the following: diabetic retinopathy, glaucoma, age-related macular degeneration, retinitis pigmentosa, including rare and genetic diseases such as congenital cataracts, as well as other eye conditions such as ocular inflammation/uveitis, refractive error, low vision, and corneal injury. Basic, translational, or epidemiological research may be proposed. Clinical trials will not be supported under this FOA. This FOA will use the NIH Research Project (R01) award mechanism.

087786 Secondary Analysis of Existing Datasets in Heart, Lung, and Blood National Heart, Lung, and Blood PAR-20-078 28-Oct-2020 150,000

26








Amount


Diseases and Sleep Disorders (R21 Clinical Trial Not Allowed) Institute/NIH/DHHS USD

Contact Name Ruth Kirby, BS Contact Telephone 301-435-0401



Deadline Dates (ALL) 28-Oct-2020 , 25-Nov-2020 , 26-Feb-2021 , 20-Apr-2021 , 28-Oct-2021 , 26-Nov-2021 , 26-Feb-2022 , 21-Apr-2022 , 28-Oct-2022 , 25-Nov-2022

Synopsis

The goal of this funding opportunity is to stimulate the use of existing human datasets for well-focused secondary analyses to investigate novel scientific ideas or new models, systems, tools, methods, or technologies that have the potential for significant impact on biomedical or biobehavioral research in areas relevant to the NHLBI mission. This FOA actively supports the use of existing database resources to conduct additional analyses secondary to a project's originally-intended primary purpose. Applications may be related to, but must be distinct from, the specific aims of the original data collection. It will not support the collection of new data.

096057 RFA-HL-21-001 -- Hybrid Effectiveness-Implementation Trials for Heart, Lung, Blood, and Sleep Diseases in the Inpatient Setting (U01 - Clinical Trials Required)

National Heart, Lung, and Blood Institute/NIH/DHHS RFA-HL-21-001


3,100,000 USD

Contact Name Lora Reineck, M.D., M.S. Contact Telephone 301-435-0222


Program URL Link to program URL Deadline Dates (ALL) 09-Nov-2020 [Optional][LOI/Pre-App], 09-Dec-2020

Synopsis

The purpose of this Funding Opportunity Announcement (FOA) is to support hybrid effectiveness-implementation trials for heart, lung, blood, and sleep (HLBS) diseases in the inpatient setting. NHLBI is seeking applications that propose a trial testing an implementation strategy (or strategies) that was developed utilizing an implementation research framework and that aims to increase implementation of an evidence-based practice(s). This FOA intends to support applications that propose a multidisciplinary research team that includes expertise in inpatient clinical research, implementation research, and biostatistics. Any applicant proposing a trial that meets the requirements of this FOA is eligible to apply, regardless of

27








https://grants.nih.gov/grants/guide/rfa-files/RFA-HL-21-001.html



Amount


participation in Preparing for Hybrid Effectiveness-Implementation Trials for Heart, Lung, Blood, and Sleep Diseases in the Inpatient Setting (U01) (RFA-HL-18-018).

097690 RFA-HG-20-045 -- Single-cell Profiling of Regulatory Element and Gene Activity in Relationship to Genome Function (UM1 Clinical Trial Not Allowed)

National Human Genome Research Institute/NIH/DHHS RFA-HG-20-045


8,100,000 USD

Contact Name Stephanie A. Morris, Ph.D. Contact Telephone 301-435-5738



Synopsis

The purpose of this Funding Opportunity Announcement (FOA) is to establish Mapping Centers that will generate single-cell, multi-omic maps of genes and regulatory elements in the human and mouse genomes. This will be accomplished through use of high-throughput state-of-the-art methods to profile biochemical features characteristic of genomic elements while preserving information about biological and/or spatial context. As a group, Mapping Centers will be expected to pursue studies that will provide a range of data types that will best enable the association of gene and regulatory element activity with specific cell fates and states. Mapping Centers will also enable others to perform related research by sharing approaches and standards, as well as identifying methodological strengths and weaknesses. Centers funded through this initiative will become part of the Impact of Genomic Variation on Function (IGVF) Consortium. As members of this consortium, Mapping Centers will be expected to work closely with one another and other consortium components to accelerate understanding of how genomic variation impacts human health and disease through the coordination of data collection strategies and analyses.

097698 RFA-HG-20-047 -- Developing Predictive Models of the Impact of Genomic Variation on Function (U01 Clinical Trial Not Allowed)



4,725,000 USD

Contact Name Daniel Gilchrist, Ph.D. Contact Telephone 301-402-0911


28





https://grants.nih.gov/grants/guide/rfa-files/RFA-HG-20-045.html






Amount



Synopsis

This FOA seeks applications for Predictive Modeling Projects that will develop and apply innovative computational models to predict the impact of genomic variation on genome function and/or phenotype and generate a catalog of variant effects. Projects will also enable others to perform related research by sharing approaches and standards and by identifying methodological strengths and weaknesses. Projects funded through this initiative will become part of the Impact of Genomic Variation on Function Consortium. As members of this Consortium, predictive modeling projects will be expected to work closely with one another and other Consortium components to accelerate understanding of how genomic variation impacts human health and disease.

097682 RFA-HG-20-043 -- Systematic Characterization of Genomic Variation on Genome Function and Phenotype (UM1 Clinical Trial Not Allowed)



6,300,000 USD

Contact Name Mike Pazin, Ph.D. Contact Telephone 301-496-7531



Synopsis

This FOA seeks applications to experimentally correlate genomic variants with their effects on genomic function. This will be accomplished by performing systematic perturbation; collecting data on the effects of non-coding and protein-coding genomic variation on molecular, cellular, and organismal phenotypes; generating a catalog of these variant effects; and assisting in a group predictive modeling effort using the data. This will also be accomplished by enabling others to perform related research by sharing approaches and standards, as well as identifying methodological strengths and weaknesses. Centers funded through this initiative will become part of the Impact of Genomic Variation on Function (IGVF) Consortium. As members of this Consortium, functional characterization centers will be expected to work closely with one another and other Consortium components to accelerate understanding of how genomic variation impacts human health and disease through the coordination of data collection strategies and analyses.

097683 RFA-HG-20-044 -- Defining Genomic Influence on Gene Network Regulation (U01 Clinical Trial Not Allowed)



4,500,000 USD

29










Amount


Contact Name Daniel Gilchrist, Ph.D. Contact Telephone 301-402-0911



Synopsis

This FOA seeks applications for research projects to explore the effects of genomic variation on phenotypes at the network level. Research projects supported through this FOA will measure changes in the activity of genes and regulatory elements during biological transitions and use generalizable analytical approaches to understand network-level relationships among genomic variation, functional elements, genes, and phenotypes related to human health and disease. Funded projects will also enable others to perform related research by sharing approaches and standards, as well as identifying methodological strengths and weaknesses. Projects funded through this initiative will become part of the Impact of Genomic Variation on Function Consortium. As members of this Consortium, network projects will be expected to work with one another and other Consortium components to accelerate understanding of how genomic variation impacts human health and disease.

097693 RFA-HG-20-046 -- Genomic Variation and Function Data and Administrative Coordinating Center (U24 Clinical Trial Not Allowed)



16,500,000 USD

Contact Name Stephanie A. Morris, Ph.D. Contact Telephone 301-435-5738



Synopsis

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications for the Genomic Variation and Function Data and Administrative Coordinating Center (DACC). The DACC will serve as the coordinating center for the Impact of Genomic Variation on Function (IGVF) Consortium and will be responsible for establishing a resource of consortium generated data, metadata, analyses, methods, and tools, and coordination of consortium activities. The DACC will also be expected to facilitate consortium-led analyses and outreach to the broader research community, especially the dissemination of the consortium generated resource to enable others to perform related research. As a member of the IGVF Consortium,

30









Amount


the DACC will work closely with all consortium components to accelerate understanding of how genomic variation impacts human health and disease through the coordination of data collection strategies and analyses.

096546 Nonhuman Primate Reagent Resource (U24 Clinical Trial Not Allowed) National Institute of Allergy and Infectious Diseases/NIH/DHHS RFA-AI-20-043


Not Specified

Contact Name Julia Shaw, Ph.D. Contact Telephone 240-627-3711



Synopsis

This Funding Opportunity Announcement (FOA) solicits applications for an immunologic reagent resource to support and facilitate the optimal use of nonhuman primate (NHP) models for vaccine and adjuvant development, transplantation, and infectious and immune-mediated diseases. This Nonhuman Primate Reagent Resource will identify, obtain, develop, characterize, evaluate, produce, and distribute to the scientific community key immunologic reagents for NHP research that are not commercially available or, if commercially available, are not optimized for use in NHPs. In addition, the resource will develop and provide a public website that includes a searchable database of information about immunologic reagents, commercial and non-commercial, that cross-react with NHP cells or proteins. The research tools generated and provided through this initiative will enable and accelerate NHP research on cures, vaccines, and treatments for immune-mediated diseases and emerging and reemerging infectious diseases.

098066 Notice of Special Interest (NOSI): Availability of Emergency Awards for Limited Clinical Trials to Evaluate Therapeutic and Vaccine Candidates Against SARS-CoV-2

National Institute of Allergy and Infectious Diseases/NIH/DHHS NOT-AI-20-065 14-Sep-2020 Not

Specified

Contact Name Diane Post, Ph.D. Contact Telephone 240-627-3348


Program URL Link to program URL Deadline Dates (ALL) 14-Sep-2020 , 14-Oct-2020 , 14-Nov-2020 , 14-Dec-2020 , 14-Jan-2021 , 14-Feb-2021 , 14-Mar-2021 , 14-Apr-2021 , 14-May-

31



https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-043.html





https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-065.html



Amount


2021 , 14-Jun-2021 , 14-Jul-2021 , 14-Aug-2021 , 14-Sep-2021

Synopsis

This Notice of Special Interest encourages cooperative agreement applications for implementation of investigator-initiated high-risk clinical trials, as defined by NIAID in PAR-18-633 and NOT-AI-16-084, that will augment ongoing and planned clinical trials of therapeutic and vaccine candidates directed against SARS-CoV-2 to evaluate: SARS-CoV-2 candidate vaccines non-vaccine biomedical prevention of SARS-CoV-2 infection and/or COVID-19 therapeutic approaches to treat COVID-19

098111 NIAID New Innovators Awards (DP2 Clinical Trial Not Allowed) National Institute of Allergy and Infectious Diseases/NIH/DHHS PAR-20-259 02-Nov-2020 1,500,000

USD

Contact Name Diane Lawrence, Ph.D. Contact Telephone 240-627-3202


Program URL Link to program URL Deadline Dates (ALL) 02-Nov-2020 , 14-Oct-2021 , 14-Oct-2022

Synopsis

The NIAID New Innovator Award supports a postdoctoral or newly independent Early Stage Investigator of exceptional creativity who proposes novel, original and insightful research concepts with the potential to produce a major impact, test scientific paradigms, or advance key concepts on broad, important problems in biomedical research of priority to NIAID. Applications proposing unexpected convergence of disciplines, new scientific directions, or the use of novel methodologies are encouraged. Applications from individuals with diverse backgrounds and in any topic relevant to the mission of NIAID are welcome.

098450 NIAID/DAIT Regulatory Management Center (RMC) National Institute of Allergy and Infectious Diseases/NIH/DHHS 75N93020R00015 18-Nov-2020 Not

Specified

Contact Name Albert Nguyen Contact Telephone



Synopsis Presolicitation Notice Information Introduction The National Institute of Allergy and Infectious Diseases (NIAID), National

32






https://beta.sam.gov/opp/fd7c294ac8b1484f89d2e4d0b5a7c475/view



Amount


Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID, Division of Allergy, Immunology, and Transplantation (DAIT) has a requirement to solicit offers for a contract to support regulatory management activities in support of NIAID-funded clinical trials and clinical studies of immune mediated diseases. Description Research supported and conducted by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (DHHS), strives to better understand, treat and ultimately prevent immunologic, infectious, and allergic diseases. The NIAID Division of Allergy, Immunology, and Transplantation (DAIT) supports extramural basic, nonclinical and clinical research that focuses on protective immune responses and immune-mediated diseases through grants and contracts awarded to domestic and foreign organizations. A critical component of the Division’s mission targets clinical research to develop new and/or improved therapies and prevention strategies through rigorous evaluation of the safety and efficacy of investigational products and approaches in clinical studies to elucidate underlying mechanisms, studies to develop and evaluate surrogate/biomarkers of disease stage, severity and progression, and clinical studies of natural history, genetics/genomics and/or other “omic”, and lifetime exposures. Research encompasses a broad range of immune-mediated diseases, including: (i) allergic diseases and asthma; (ii) autoimmune disorders; (iii) immune-mediated rejection in solid organ, tissue and cell transplantation; (iv) primary immune deficiency disorders;(v) and other immune system disorders and treatments to enhance immune functions. Another component of DAIT- NIAID’s mission focuses on the planning and implementation of research, development, and evaluation of medical countermeasures for radiation injury. All NIAID funded clinical research studies and trials (whether or not conducted under US IND or outside-US IND-Equivalent), must be conducted in accordance with US-federal regulations and guidelines, International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) Guidelines, as well as countryspecific regulations and requirements. As the sponsor of US Investigational New Drug Applications (IND) and Investigational Device Exemption (IDE) applications as well as country-specific Regulatory Health Authority (RHA) Applications for DAIT-NIAID-supported clinical trials, DAIT-NIAID is required to provide study-specific regulatory management activities to ensure: (i) compliance with the applicable regulations; and (ii) study/trial data integrity. Any responsible offeror may submit a proposal which will be considered by the Agency. This RFP will be available electronically on/about September 04, 2020 and may be accessed through beta.SAM.gov. This notice does not commit the Government to award a contract. No collect calls will be accepted. No facsimile transmissions will be accepted. For this solicitation, the NIAID requires proposals to be submitted electronically via the NIAID electronic Contract Proposal Submission (eCPS) website. For directions on using eCPS, go to the website https://ecps.nih.gov and then click on "How to Submit." Additional beta.sam.gov information

077309 Supplements to Advance Research (STAR) from Projects to Programs (Admin Supp- Clinical Trial Not Allowed)

National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS

PA-18-914 04-Nov-2020 300,000 USD

33





Amount


Contact Name Heiyoung Park, Ph.D. Contact Telephone 301-594-3507


Program URL Link to program URL Deadline Dates (ALL) 04-Nov-2020 , 05-Apr-2021

Synopsis

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) invites applications intended to innovation and exploration of high-risk ideas by providing supplemental funding to investigators. The STAR Program is designed to allow investigators to expand upon and explore new opportunities within the broad scope of a currently funded, peer-reviewed research project to facilitate the transition from a single project to a research program. This supplemental award program will support activities that provide the basis to effectively allow investigators to transition from a single, structured research project to multiple, related projects with interconnected goals but with clearly distinct focus and approaches. For the purpose of the STAR Program, eligible investigators will have had a first NIAMS-supported R01 initially awarded with early stage investigator (ESI) status and must have successfully renewed this project. Eligible investigators for the STAR award have never held more than two R01-equivalent grants (https://grants.nih.gov/grants/glossary.htm#R) including the renewed R01 that was funded by NIAMS with ESI status. This FOA will use the NIH Administrative Supplement award mechanism.

071567 Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)


PAR-18-597 03-Nov-2020 450,000 USD

Contact Name James Witter, M.D., Ph.D. Contact Telephone 301-594-1963



Synopsis

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) invites applications to pursue clinical observational (CO) studies to obtain data necessary for designing clinical studies for musculoskeletal, rheumatic, or skin diseases or conditions. A future clinical study may include a clinical trial or an observational study. Research data from observational studies supported by this FOA can enhance clinical study design by providing essential information about

34


https://grants.nih.gov/grants/guide/pa-files/PA-18-914.html







Amount


disease symptoms, stages and timing of disease progression, comorbid conditions, availability of potential research participants, and outcomes that are important to patients. They also can facilitate efforts to develop and/or validate objective biomarkers or subjective outcome measures for use in a future clinical study. Applicants to this FOA are encouraged to propose studies that address significant obstacles or questions in the design of a clinical project, such as determining the appropriate primary or secondary outcome measures, or identifying the stages of disease during which patients are most likely to respond to an intervention. Only observational studies will be supported through this FOA. This program will use the NIH R01 Research Project Grant award mechanism.

071545 Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R21 Clinical Trial Required)


PAR-18-595 03-Nov-2020 400,000 USD

Contact Name James Witter, M.D., Ph.D. Contact Telephone 301-594-1963



Synopsis

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) invites applications designed to facilitate clinical trials that can be completed within a limited timeframe and budget. A broad range of types of exploratory studies may be submitted to this FOA. The trials must address research questions related to the mission and goals of the NIAMS and may evaluate interventions with drugs, biologics, devices, or surgical, dietary, behavioral or rehabilitation therapies. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

071544 NIAMS Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)


PAR-18-594 03-Nov-2020 Not Specified

Contact Name Shahnaz Khan, MPH Contact Telephone 301-451-9893



35











Amount



Synopsis

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) cooperative agreement (U01) applications for implementation of investigator-initiated interventional clinical trials (all phases). Applications for clinical trials submitted to the NIAMS are normally expected to go through a two-part process, which begins with an R34 planning phase (Part 1) followed by an application for the U01 (Part 2). Investigators who have completed all necessary pre-trial planning and preparation through other means may apply for a NIAMS U01 without having applied for a R34. The NIAMS expects trials to be hypothesis-driven and have the potential for high impact within the research mission of the NIAMS. This FOA will utilize the NIH U01 Research Project – Cooperative Agreements award mechanism.

088239 NIAMS Clinical Trial Planning Grant (R34) - Clinical Trial Not Allowed National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS

PAR-20-090 02-Nov-2020 300,000 USD

Contact Name NIAMS Clinical Research Team Contact Telephone


Program URL Link to program URL Deadline Dates (ALL) 02-Nov-2020 , 01-Mar-2021 , 01-Jul-2021 , 01-Nov-2021 , 01-Mar-2022 , 01-Jul-2022 , 01-Nov-2022

Synopsis

This Funding Opportunity Announcement (FOA) will support planning grants for investigator-initiated clinical interventional trials. The R34 planning grant is designed to enable the necessary planning, design, and preparation of documentation prior to implementation of investigator-initiated clinical trials. Completion of the agreed upon milestones of an R34 planning grant or documentation that planning has been addressed is required prior to submission of an application through a NIAMS U01 clinical trial implementation application that will support the actual implementation and conduct of the study. The planning should facilitate the launching of a trial that is hypothesis-driven, milestone-defined, and has the potential for high impact within the research mission of the NIAMS.

081811 RFA-AR-20-002 -- Mechanistic Ancillary Studies to Ongoing Clinical Projects (R21 Clinical Trial Not Allowed)


RFA-AR-20-002 01-Nov-2020 [Optional][LOI/Pre-App]

400,000 USD


36








Amount




Synopsis

This Funding Opportunity Announcement (FOA) solicits applications that propose to conduct time-sensitive mechanistic ancillary studies related to the NIAMS mission in conjunction with privately or publicly funded, ongoing clinical projects. The ongoing “parent” clinical project can be an interventional clinical trial, or a clinical study such as an observational study that will be actively collecting patient samples or clinical data. The “parent” project(s) should provide a cohort of well-characterized patients, infrastructure, data, and biological samples for the ancillary study. Applications submitted in response to this FOA will undergo an accelerated review and award process. The objective of this FOA is to provide a flexible mechanism to leverage established resources and maximize the return on existing investments in parent projects. Successful ancillary studies will enhance the scientific content and value of the parent projects, improve the research community’s understanding of a disease or organ system in the NIAMS portfolio, and thus may identify novel targets for diagnosis, treatment, and prevention of disease.

081806 RFA-AR-20-001 -- Mechanistic Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)


RFA-AR-20-001 01-Nov-2020 [Optional][LOI/Pre-App]

1,200,000 USD




Synopsis

This Funding Opportunity Announcement (FOA) solicits applications that propose to conduct time-sensitive mechanistic ancillary studies related to the NIAMS mission in conjunction with privately or publicly funded, ongoing clinical projects. The ongoing “parent” clinical project can be an interventional clinical trial, or a clinical study such as an observational study that will be actively collecting patient samples or clinical data. The “parent” project(s) should provide a cohort of well-characterized patients, infrastructure, data, and biological samples for the ancillary study. Applications submitted in response to this FOA will undergo an accelerated review and award process. The objective of this FOA is to provide a flexible mechanism to leverage established resources and maximize the return on existing investments in parent projects. Successful

37


https://grants.nih.gov/grants/guide/rfa-files/RFA-AR-20-002.html




https://grants.nih.gov/grants/guide/rfa-files/RFA-AR-20-001.html



Amount


ancillary studies will enhance the scientific content and value of the parent projects, improve the research community’s understanding of a disease or organ system in the NIAMS portfolio, and thus may identify novel targets for diagnosis, treatment, and prevention of disease.

097373 RFA-RM-20-018 -- Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa) Open Data Science Platform and Coordinating Center (U2C – Clinical Trial Not Allowed)

National Institute of Biomedical Imaging and Bioengineering/NIH/DHHS

RFA-RM-20-018 03-Nov-2020 [Optional][LOI/Pre-App]

11,250,000 USD

Contact Name Tiffani Bailey Lash, Ph.D. Contact Telephone 301-496-4778



Synopsis

This Funding Opportunity Announcement (FOA) seeks applications for the development of an Open Data Science Platform and Coordinating Center as part of a broader initiative entitled Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa). The goal of DS-I Africa is to spur new health discoveries and catalyze innovation in healthcare, public health, and health research on the continent through application of data science. The FOA is comprised of two components – the DS-I Africa Open Data Science Platform (ODSP) and Coordinating Center (CC) – funded via one U2C award. The ODSP core will develop and maintain a scalable data-sharing gateway available to the research community with access to disparate types of open and controlled-access data and tools, generated from the DS-I Africa Research Hubs as well as other existing sources. The CC core will provide the organizational framework for the management, direction, and overall coordination of all common DS-I Africa consortium activities. The cooperative agreement will be awarded to an African academic or other non-profit institution. Multisectoral partnerships with other organizations in Africa, the U.S., or other countries are encouraged.

075633 The Role of Epitranscriptomics in Development and Disease (R21 - Clinical Trial Not Allowed)

National Institute of Child Health and Human Development/NIH/DHHS

PAR-18-831 07-Nov-2020 275,000 USD

Contact Name Stuart B. Moss, PhD Contact Telephone 301-435-6979


38











Amount



Synopsis

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the scientific community to support outstanding research in the area of epitranscriptomics, i.e., the chemical modifications of RNA. Evidence is accumulating that RNA modifications regulate the function of both coding and noncoding RNAs, suggesting that these modifications are involved in both development, and in health and disease. Yet the extent and types of these RNA modifications as well as their roles in particular biological processes remain either poorly understood or not known. The goal of the FOA is to promote research into the role of RNA chemical modifications in the initiation and progression of various developmental processes and disease states and conditions relevant to the scientific mission of the participating ICs.

075624 The Role of Epitranscriptomics in Development and Disease (R01 - Clinical Trial Not Allowed)


PAR-18-830 07-Nov-2020 499,999 USD

Contact Name Stuart B. Moss, PhD Contact Telephone 301-435-6979



Synopsis

The purpose of this Funding Opportunity Announcement (FOA) is to encourage applications from the scientific community to support outstanding research in the area of epitranscriptomics, i.e., the chemical modifications of RNA. Evidence is accumulating that RNA modifications regulate the function of both coding and noncoding RNAs, suggesting that these modifications are involved in both development, and in health and disease. Yet the extent and types of these RNA modifications as well as their roles in particular biological processes remain either poorly understood or not known. The goal of the FOA is to promote research into the role of RNA chemical modifications in the initiation and progression of various developmental processes and disease states and conditions relevant to the scientific mission of the participating ICs.

086438 Human-Animal Interaction (HAI) Research (R21 Clinical Trial Optional) National Institute of Child Health and Human Development/NIH/DHHS

PAR-20-033 30-Nov-2020 275,000 USD

Contact Name Layla Esposito, Ph.D.

39









Amount


Contact Telephone 301-435-6888 Contact Email [email protected]


Deadline Dates (ALL) 30-Nov-2020 , 30-Nov-2021

Synopsis

This Funding Opportunity Announcement (FOA) invites grant applications for research to examine 1) the impact of Human-Animal Interactions (HAI) on typical and atypical child development and health; 2) the evaluation of animal-assisted intervention for children and adults with disabilities or in need of rehabilitative services; 3) the effects of animals on public health, including cost effectiveness of involving animals in reducing and preventing disease.


PAR-20-032 30-Nov-2020 100,000 USD

Contact Name Layla Esposito, Ph.D. Contact Telephone 301-435-6888


Program URL Link to program URL Deadline Dates (ALL) 30-Nov-2020 , 30-Nov-2021

Synopsis

This Funding Opportunity Announcement (FOA) invites grant applications for research to examine 1) the impact of Human-Animal Interactions (HAI) on typical and atypical child development and health; 2) the evaluation of animal-assisted intervention for children and adults with disabilities or in need of rehabilitative services; 3) the effects of animals on public health, including cost effectiveness of involving animals in reducing and preventing disease.


PAR-20-031 30-Nov-2020 2,499,995 USD

Contact Name Layla Esposito, Ph.D. Contact Telephone 301-435-6888


40










Amount



Deadline Dates (ALL) 30-Nov-2020 , 30-Nov-2021

Synopsis

This Funding Opportunity Announcement (FOA) invites grant applications for research to examine 1) the impact of HAI on typical and atypical child development and health; 2) the evaluation of animal-assisted intervention for children and adults with disabilities or in need of rehabilitative services; 3) the effects of animals on public health, including cost effectiveness of involving animals in reducing and preventing disease.

094675 RFA-HD-21-006 -- Elucidating the Role of Nutrition in Care and Development of Preterm Infants (R01 Clinical Trial Optional)


RFA-HD-21-006 30-Oct-2020 [Optional][LOI/Pre-App]

2,499,995 USD

Contact Name Daniel J. Raiten, PhD Contact Telephone 301-435-7586



Synopsis This Funding Opportunity Announcement (FOA) invites grant applications that address priority gaps in understanding the role of nutrition in the care and development of preterm infants.

076073 Drug Transport Across the Blood-Testis and Blood-Epididymal Barriers (R61/R33 - Clinical Trial Not Allowed)



Contact Name Daniel S. Johnston, PhD Contact Telephone 301-827-4663



Synopsis National Institute of Child Health and Human Development (NICHD) invites applications for in vivo research to elucidate the

41





https://grants.nih.gov/grants/guide/rfa-files/RFA-HD-21-006.html







Amount


chemical features of non-native molecules that facilitate passage across the blood-testis and/or blood-epidydimal barriers. This FOA will use the NIH R61/R33 Exploratory/Developmental Phased Award mechanism.

096745 RFA-HD-21-020 -- Non-invasive Diagnostics to Improve Gynecologic Health (R43/R44 Clinical Trial Optional)


RFA-HD-21-020 10-Nov-2020 [Optional][LOI/Pre-App]

Not Specified

Contact Name Candace M. Tingen, PhD Contact Telephone 301-435-6971



Synopsis

The purpose of this funding opportunity announcement (FOA) is to encourage small businesses to collaborate with scientists and clinicians in the field of gynecologic health to develop, advance, and validate new devices and methods for non-invasive diagnosis and/or screening of endometriosis, adenomyosis, and/or uterine fibroids. Projects supported will aim to shorten the time to diagnosis, decrease the invasiveness of current techniques, and/or improve accessibility, safety, convenience, and costs of diagnosis and/or screening.

097649 RFA-HD-21-025 -- Maternal and Pediatric Precision in Therapeutics (MPRINT) Knowledge and Research Coordination Center (P30 Clinical Trial Not Allowed)



Not Specified

Contact Name Lesly-Anne Samedy-Bates, M.S., Pharm.D., Ph.D. Contact Telephone 301-827-3241



Synopsis This Funding Opportunity Announcement (FOA) invites applications to form the Knowledge and Research Coordination Center (KRCC) of the NICHD’s Maternal and Pediatric Precision in Therapeutics (MPRINT) Hub. The MPRINT Hub will serve as a national resource for expertise in maternal and pediatric therapeutics to conduct and foster therapeutics-focused research in

42












Amount


obstetrics, lactation, and pediatrics while enhancing inclusion of people with disabilities. By serving as a national resource, it will aggregate, present, and expand the available knowledge, tools, and expertise in maternal and pediatric therapeutics to the broader research, regulatory science, and drug development communities. The MPRINT KRCC will coordinate and support the operations of the entire MPRINT Hub, interface with Centers of Excellence in Therapeutics (CETs; RFA-HD-21-026) and develop a web portal to access an underlying curated knowledge base of maternal and pediatric pharmacology and therapeutics. This knowledge base will aggregate and identify knowledge deficits in the principles of maternal and pediatric therapeutics including pharmacokinetics, pharmacodynamics, genetics, proteomics, and metabolomics that inform drug development and regulatory science. The MPRINT KRCC will serve as the primary administrative component and public-facing component of the MPRINT Hub as well as a conduit to the resources in its other components such as the MPRINT CETs. Additionally, the MPRINT KRCC will oversee an Opportunity Pool of funds to address emergent needs in support of national research in maternal and pediatric therapeutics.

097652 RFA-HD-21-026 -- Maternal and Pediatric Precision in Therapeutics (MPRINT) Centers of Excellence in Therapeutics (P50 Clinical Trial Optional)



425,000 USD

Contact Name Zhaoxia Ren, MD, PhD Contact Telephone 301-402-9340



Synopsis

This Funding Opportunity Announcement (FOA) invites applications to form Centers of Excellence in Therapeutics (CETs) as part of the NICHD’s Maternal and Pediatric Precision in Therapeutics (MPRINT) Hub. The MPRINT Hub will serve as a national resource for expertise in maternal and pediatric therapeutics to conduct and foster therapeutics-focused research in obstetrics, lactation, and pediatrics while enhancing inclusion of people with disabilities. By serving as a national resource, it will aggregate, present, and expand the available knowledge, tools, and expertise in maternal and pediatric therapeutics to the broader research, regulatory science, and drug development communities. The MPRINT CETs will work together and with the MPRINT Knowledge and Research Coordination Center (KRCC; RFA-HD-21-025), the central coordinating center of the MPRINT Hub, to serve as a national resource for knowledge and expertise in maternal and pediatric pharmacology and as a research center to close deficits in knowledge and technical expertise. The MPRINT CETs will conduct cutting edge clinical, translational, basic, and/or data sciences research, provide resources, and generate novel tools and approaches to advance and accelerate research and regulatory science in maternal and pediatric therapeutics. The MPRINT KRCC will serve as the

43








Amount


primary public-facing component of the MPRINT Hub and as a conduit to the resources of the MPRINT CETs.

087522 National Dental Practice-Based Research Network Infrastructure Access (X01 Clinical Trial Not Allowed)

National Institute of Dental and Craniofacial Research/NIH/DHHS PAR-20-073 01-Sep-2020 Not

Specified

Contact Name Dena Fischer, DDS, MSD, MS Contact Telephone 301-594-4876


Program URL Link to program URL Deadline Dates (ALL) 01-Sep-2020 , 02-Nov-2020 , 01-Sep-2021 , 01-Sep-2022

Synopsis

The National Institute of Dental and Craniofacial Research (NIDCR) is continuing support for research conducted within a dental Practice-Based Research Network (PBRN). The National Dental PBRN Administrative and Resource Center and National Coordinating Center support the infrastructure for and implementation of multiple clinical studies. This Funding Opportunity Announcement (FOA) is seeking applications for small developmental/exploratory, feasibility (pilot), and/or survey studies of practitioners and/or patients to be conducted in the National Dental PBRN. Successful X01 applicants will be given access to the National Dental PBRN infrastructure to support an individual project. Successful applications will utilize the resources of and be funded through the National Dental PBRN Administrative and Resource Center and/or National Coordinating Center for study planning and implementation. This FOA seeks projects up to two years in length. The main goals of the dental PBRN are to streamline the implementation of national oral health research studies in dental practices on topics of importance to practitioners and their patients, to provide evidence useful in daily patient care, and to facilitate the translation of research findings into clinical practice. This FOA encourages applications proposing research studies that align with the goals of the dental PBRN.

096486 RFA-DE-21-001 --Characterizing Causal Mechanisms to Prvent Dental Fear and Anxiety (R01 Basic Experimental Studies with Humans Required)

National Institute of Dental and Craniofacial Research/NIH/DHHS RFA-DE-21-001


Not Specified

Contact Name Elise L. Rice, PhD Contact Telephone 301-593-4814



44









https://grants.nih.gov/grants/guide/rfa-files/RFA-DE-21-001.html



Amount


Deadline Dates (ALL) 10-Oct-2020 [Optional][LOI/Pre-App], 10-Nov-2020

Synopsis

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research to test causal mechanisms underlying the etiology or prevention of dental fear, anxiety, or phobia. Novel insights about the causal forces that initiate, shape, or impede the development of dental fear will be essential for informing evidence-based interventions to prevent dental fear. This FOA is for basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants.” These studies fall within the NIH definition of a clinical trial and also meet the definition of basic research. Types of studies that should submit under this FOA include studies that prospectively assign human participants to conditions (i.e., experimentally manipulate independent variables) and that assess biomedical or behavioral outcomes in humans for the purpose of understanding the fundamental aspects of phenomena without specific application towards processes or products in mind. Studies conducted with specific applications toward processes or products in mind should submit under the appropriate ‘Clinical Trials Required’ or ‘Clinical Trial Optional’ FOA.

087564

RFA-DK-19-028 -- Support for Small Business Innovation Research (SBIR) to Development and Testing of New Technologies and Bioengineering Solutions for the Advancement of Cell Replacement Therapies for Type 1 Diabetes (R43/R44 Clinical Trial Not Allowed)

National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS

RFA-DK-19-028 03-Oct-2020 [Optional][LOI/Pre-App]

Not Specified

Contact Name Guillermo Arreaza-Rubin, M.D. Contact Telephone 301-594-4724



Synopsis This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications for funding to perform research leading to the development of novel and supportive technologies for the improvement of cell replacement interventions using novel methods, biomaterials and devices for type 1 diabetes (T1D) treatment.

087974 RFA-DK-19-026 -- New Investigator Gateway Awards for Collaborative T1D Research (R03 Clinical Trial Not Allowed)



200,000 USD

Contact Name Kristin M. Abraham, Ph.D Contact Telephone 301-451-8048

45






https://grants.nih.gov/grants/guide/rfa-files/RFA-DK-19-028.html





Amount




Synopsis

The New Investigator Gateway Award in T1D Research is designed to ensure that a robust pipeline of talented new investigators will continue to embark on successful careers in T1D research. In addition to providing support for preliminary research, the Gateway program provides an opportunity for new Program Directors/Principal Investigators (PD/PIs) to pursue their studies within the intellectual environment of a select number of large, ongoing collaborative research programs. Embedding awardees within an established scientific framework in each of these consortia will provide unique opportunities for New andEarly Stage Investigators to increase their understanding of key questions in the field, to network, and to establish unique and potentially long-lasting collaborations that will propel their careers forward. It is anticipated that the Gateway award will providethe support needed to enhancethe success of futureR01 submissions from NewInvestigators interested in pursuing careersin T1D research.

087378

RFA-DK-19-027 -- Support for Small Business Innovation Research (SBIR) to Develop New Technologies for Development and Integration of Novel Components for Open and Closed Loop Hormone Replacement Platforms for T1D Therapy (R43/R44 Clinical Trial Not Allowed)



Not Specified

Contact Name Guillermo Arreaza-Rubin, M.D. Contact Telephone 301-594-4724



Synopsis

This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications for funding to perform research leading to the development of new approaches to create devices/components with enhanced accuracy and less patient burden that will represent real advancements regarding safety and effectiveness of glucose control technologies and their integration into open and closed loop hormone replacement systems.

080282 High impact, Interdisciplinary Science in NIDDK Research Areas (RC2 National Institute of Diabetes and PAR-19-202 03-Nov-2020 Not

46













Amount


Clinical Trial Optional) Digestive and Kidney Diseases/NIH/DHHS

Specified

Contact Name Corinne M. Silva, Ph.D. Contact Telephone 301-451-7335



Synopsis

The purpose of the High Impact, Interdisciplinary Science grants program is to support high impact ideas that may lay the foundation for new fields of investigation within the mission of NIDDK. The interdisciplinary approach encouraged by this FOA is envisioned to generate a research resource and/or foster discovery-based or hypothesis-generating science that can have a significant impact on the broader scientific community. This FOA seeks novel approaches in areas that address specific knowledge gaps, scientific opportunities, new technologies, data generation, or research methods that will advance the area in significant ways designed to accelerate scientific progress in the understanding, treatment, and prevention of diseases within the mission of NIDDK.

083080 Early-Stage Preclinical Validation of Therapeutic Leads for Diseases of Interest to the NIDDK (R01 Clinical Trial Not Allowed)



Contact Name Aaron C. Pawlyk, Ph.D. Contact Telephone 301-451-7299



Synopsis

The goal of this Funding Opportunity Announcement (FOA) is to support translational research that provides strong justification for later-phase therapeutics discovery and development efforts in health-related outcomes relevant to the National Institute of Diabetes and Digestive and Kidney Diseases. This includes outcomes relevant to obesity, diabetes and related aspects of endocrinology and metabolism, digestive diseases, liver diseases, nutrition, kidney and urological diseases, and hematology. Additional information concerning programmatic areas at NIDDK is available

47










Amount


at www.niddk.nih.gov/research-funding/research-programs/Pages/default.aspx and applicants are strongly encouraged to discuss research priorities with the Scientific Contact. The objective of this FOA is to stimulate early-stage preclinical validation of therapeutic leads (that need not be finalized therapeutics, henceforth called "therapeutic leads") such as small molecules or non-viral biologics that are not currently a focus within the biotechnology and pharmaceutical industries. It is expected that there is significant novelty in the target, small molecule, or non-viral biologic and in how the resulting therapeutic would differentiate from existing therapies. This must be articulated clearly in the application. It is not intended to support research focused on understanding normal biology, disease processes, generating lists of putative new targets, or identifying new therapeutic uses for existing compounds. At the end of the project period, a successful project will have provided a significant contribution to the data supporting the validity around a therapeutic such that it can advance further through other funding mechanisms, such as the small business program (https://sbir.nih.gov/niddk/index).

096928 RFA-DK-20-021 -- Mechanistic Studies of the Interaction between SARS-CoV-2/COVID-19 and Diseases and Organ Systems of Interest to NIDDK (R01 Clinical Trial Optional)


RFA-DK-20-021 16-Nov-2020 [Optional][LOI/Pre-App]

750,000 USD

Contact Name Maren R. Laughlin, Ph.D. Contact Telephone 301-594-8802



Synopsis

The purpose of this Funding Opportunity Announcement (FOA) is to support basic and clinical mechanistic research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) susceptibility, routes of infection, course of disease, morbidity and mortality in people with pre-existing diseases, or adverse acute or chronic outcomes in organs, tissues, and biological systems of specific interest to NIDDK. These include diabetes and other metabolic diseases, obesity, and endocrine, digestive, liver, pancreas, kidney, urological, and hematologic tissues and diseases.

076879 Elucidating the Role of the Autonomic Nervous System in Peripheral Metabolism and Metabolic Disease through the Application of Novel Tools and Methodologies (RC2 Clinical Trial Optional)



Contact Name Karen Teff, Ph.D. Contact Telephone 301-594-8803

48











Amount




Synopsis

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications for scientific advancements addressing the role of the autonomic nervous system in the regulation of peripheral metabolism and its role in diabetes, obesity and related metabolic disease. Interdisciplinary teams may propose to develop resources in the form of novel tools or methodologies that when applied to the autonomic nervous system will contribute to elucidating its functional role in metabolism. Alternatively, teams may focus on novel approaches to address specific knowledge gaps or scientific questions that will significantly contribute to our understanding of role of the autonomic nervous system in metabolism with the goal of accelerating scientific progress in the treatment and prevention of metabolic disease. This FOA will use the NIH RC2 High Impact Research and Research Infrastructure Programs award mechanism.

095678 RFA-DK-20-008 -- George M. O'Brien Urology Cooperative Research Centers Program (U54 Clinical Trial Optional)



5,000,000 USD

Contact Name Tamara G. Bavendam, MD, MS Contact Telephone 301-594-4733



Synopsis

This Funding Opportunity Announcement (FOA) seeks applications for the George M. O’Brien Urology Cooperative Research Centers Program (U54). This program will foster multi- and interdisciplinary collaboration between basic, translational, and clinical researchers with diverse expertise to address questions of underlying etiology and biological and clinical features of benign genitourinary diseases and disorders within the NIDDK’s mission. In addition, the program will serve as a national resource for the larger urologic research community and provide opportunities for educational enrichment and engagement of investigators in pilot projects that target innovative science and researchers new to urology. All efforts will address the overall goal of improving prevention and clinical management of benign genitourinary disorders through research excellence, enhanced sharing of resources and access to core services, and establishment of a robust research community trained to address the Nation’s biomedical research needs for benign genitourinary diseases and disorders.

49









Amount


096740 RFA-DK-20-016 -- Continuation of the Human Pancreas Analysis Program (HPAP) for Type 1 Diabetes (HPAP-T1D) (U01 Clinical Trial Not Allowed)



18,000,000 USD

Contact Name Xujing Wang Contact Telephone 301-451-2862



Synopsis

This Funding Opportunity Announcement (FOA) invites a single cooperative agreement application to continue the mission of the existing Human Pancreas Analysis Program (HPAP). This FOA will support one team of investigators with combined expertise in human pancreas physiology and pathophysiology; collection, processing and multimodal analysis of human pancreatic tissues; and biological database building, curation and management, that will be tasked to: 1) identify, collect and intensively characterize primary pancreatic tissues from patients with type 1 diabetes (T1D) or at risk of developing the disease, as well as age-matched controls; and 2) analyze, organize and share the data resulting from the study of these tissues through the existing PANC DB open-access resource database. HPAP is a component of the Human Islet Research Network or HIRN. HIRN was created in 2014 to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional human beta cell mass.

069914 NIDDK Multi-Center Clinical Study Implementation Planning Cooperative Agreements (U34 Clinical Trial Optional)


PAR-18-423 02-Nov-2020 450,000 USD

Contact Name Tracy Rankin, Ph.D., M.P.H. Contact Telephone 301-594-4748



Synopsis NIDDK supports investigator-initiated, multi-center (three or more centers) clinical studies through a two-part process that

50












Amount


may include an implementation planning cooperative agreement (U34). The U34 is designed to: 1) Permit early peer review of the rationale for the proposed clinical study; 2) Permit assessment of the design and protocol of the proposed study; 3) Provide support for the development of documents needed for the conduct of the study, including a manual of operations; and 4) Support the development of other essential elements required for the conduct of the clinical study. The proposed clinical study should be hypothesis-driven and focus on a disease relevant to the mission of NIDDK. Consultation with NIDDK scientific staff is strongly encouraged prior to the submission of the U34 application

096867 RFA-DK-20-012 -- Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) – Scientific and Data Research Center (U01 Clinical Trial Required)



500,000 USD

Contact Name Ivonne H. Schulman, M.D. Contact Telephone 301-435-3350



Synopsis

Acute kidney injury (AKI) is associated with high morbidity, including increased risk of chronic kidney disease (CKD), end-stage kidney disease (ESKD), cardiovascular disease, and mortality. Severity, duration, and frequency of episodes of AKI as well as age, pre-existing CKD, and other comorbidities are associated with greater risks of CKD progression and death. There is limited evidence to inform recommendations for processes of care or therapeutic interventions targeting progression of kidney disease and the associated morbidity and mortality in AKI survivors. This is a missed opportunity to prevent chronic disease and premature death. The Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Consortium, composed of 3 to 4 Clinical Centers (CCs) and a Scientific and Data Research Center (SDRC), will develop and test interventions that aim to reduce morbidity compared with usual care in Stage 2 and 3 AKI survivors. This FOA pertains to the SDRC.

096863 RFA-DK-20-011 -- Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) – Clinical Centers (U01 Clinical Trial Required)



500,000 USD

Contact Name Ivonne H. Schulman, M.D. Contact Telephone 301-435-3350


51











Amount



Deadline Dates (ALL) 04-Oct-2020 [Optional][LOI/Pre-App], 04-Nov-2020

Synopsis

Acute kidney injury (AKI) is associated with high morbidity, including increased risk of chronic kidney disease (CKD), end-stage kidney disease (ESKD), cardiovascular disease, and mortality. Severity, duration, and frequency of episodes of AKI as well as age, pre-existing CKD, and other comorbidities are associated with greater risks of CKD progression and death. There is limited evidence to inform recommendations for processes of care or therapeutic interventions targeting progression of kidney disease and the associated morbidity and mortality in AKI survivors. This is a missed opportunity to prevent chronic disease and premature death. The Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Consortium composed of 3 to 4 Clinical Centers (CCs) and a Scientific and Data Research Center (SDRC) will develop and test interventions that aim to reduce morbidity compared with usual care in Stage 2 and 3 AKI survivors. This FOA pertains to the CCs.

076166 Time-Sensitive Obesity Policy and Program Evaluation (R01 Clinical Trial Not Allowed)


PAR-18-854 10-Sep-2020 Not Specified

Contact Name Mary Evans, Ph.D. Contact Telephone 301-594-4578



Deadline Dates (ALL) 10-Sep-2020 , 14-Oct-2020 , 10-Nov-2020 , 11-Dec-2020 , 11-Jan-2021 , 10-Feb-2021 , 10-Mar-2021 , 09-Apr-2021 , 10-May-2021 , 11-Jun-2021 , 09-Jul-2021 , 10-Aug-2021 , 10-Sep-2021

Synopsis

National Institutes of Health (NIH) and its participating Institutes and Centers invite applications for time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding. All applications submitted to this FOA must demonstrate that the evaluation of an obesity related policy and /or program offers an uncommon and scientifically compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications submitted to this time-sensitive FOA are not eligible for re-submission. It is intended that eligible applications selected for funding will be awarded within 4 months of the application due date. However, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that

52








Amount


timeline. This FOA will utilize the NIH R01 Research Project Grant award mechanism.

098116 RFA-DK-20-004 -- Liver Cirrhosis Network: Scientific and Data Coordination Center (U24 Clinical Trial Optional)



7,500,000 USD

Contact Name Edward Doo, MD Contact Telephone 301-451-4524



Synopsis The NIDDK is proposing the establishment of the Liver Cirrhosis Network through this Funding Opportunity Announcement which is seeking a single Scientific Data Coordination Center; and in conjunction with RFA-DK-20-003 seeking Clinical Research Centers, in order to promote clinical and translational research on cirrhosis of the liver in adults.

098115 RFA-DK-20-003 -- Liver Cirrhosis Network: Clinical Research Centers (U01 Clinical Trial Required)



1,250,000 USD

Contact Name Edward Doo, MD Contact Telephone 301-451-4524



Synopsis The NIDDK is proposing the establishment of the Liver Cirrhosis Network through this Funding Opportunity Announcement which is seeking Clinical Centers; and in conjunction with RFA-DK-20-004 seeking a single Scientific Data Coordination Center, in order to promote clinical and translational research on cirrhosis of the liver in adults.

097296 RFA-DK-20-019 -- Chronic Kidney Diseases of UnceRtain Etiology (CKDu) in Agricultural Communities (CURE) Research Consortium - Scientific Data Coordinating Center (SDCC) (U24 - Clinical Trial Not



Not Specified

53














Amount


Allowed)

Contact Name Susan R. Mendley, MD Contact Telephone 301-827-1861



Synopsis

This Funding Opportunity Announcement (FOA) invites applications for a Scientific Data Coordinating Center (SDCC) which will lead a new consortium, Chronic Kidney Disease of UnceRtain Etiology (CKDu) in Agricultural Communities (CURE), in the development and successful execution of study designs and protocols. The SDCC will provide data management and analysis, as well as overall project management for the Consortium. This collaborative research consortium will bring together a broad range of expertise and enable discovery science to understand the cause or causes of CKDu and disease progression. The Consortium will also work to identify potential therapeutic targets and public health interventions. The Consortium will consist of a Scientific Data Coordinating Center (SDCC), Field Epidemiology Sites (FES), a Renal Science Core (RSC), and the Human Health Exposure Analysis Resource (HHEAR). The Consortium will work together to finalize ethical epidemiology research designs, execute common strategies for biological sampling and environmental assessment, apply the best analytic strategies for collected samples and data, and disseminate results to the global research and public health communities. The final design of the study, as determined by the Steering Committee, may significantly vary from individual applications. It is required that all funded sites fully abide with the final harmonized design set by the Consortium Steering Committee.

097292 RFA-DK-20-017 -- Chronic Kidney Diseases of UnceRtain Etiology (CKDu) in Agricultural Communities (CURE) Research Consortium - Field Epidemiology Sites (U01 - Clinical Trial Not Allowed)



Not Specified




Synopsis This Funding Opportunity Announcement (FOA) invites applications for Field Epidemiology Sites (FES) to enroll research

54











Amount


participants in the consortium to study Chronic Kidney Disease of UnceRtain Etiology (CKDu) in Agricultural Communities (CURE). The FES will recruit, enroll and follow participants with evidence of CKDu and appropriate control participants; collect data and conduct clinical assessments; collect biological and environmental samples; and maintain partnerships with local leaders, health care providers, health ministries, or governments. This collaborative research consortium will bring together a broad range of expertise and enable discovery science to understand the cause or causes of CKDu and disease progression. The Consortium will also work to identify potential therapeutic targets and public health interventions. The Consortium will consist of a Scientific Data Coordinating Center (SDCC), Field Epidemiology Sites (FES), a Renal Science Core (RSC), and the Human Health Exposure Analysis Resource (HHEAR). The Consortium will work together to finalize ethical epidemiology research designs, execute common strategies for biological sampling and environmental assessment, apply the best analytic strategies for collected samples and data, and disseminate results to the global research and public health communities. The final design of the study, as determined by the Steering Committee, may significantly vary from individual applications. It is required that all funded sites fully abide with the final harmonized design set by the Consortium Steering Committee.

097295 RFA-DK-20-018 -- Chronic Kidney Diseases of UnceRtain Etiology (CKDu) in Agricultural Communities (CURE) Research Consortium - Renal Science Core (U01 - Clinical Trial Not Allowed)



Not Specified




Synopsis

This Funding Opportunity Announcement (FOA) invites applications for a Renal Science Core (RSC) to support and provide scientific guidance as part of a new consortium to study Chronic Kidney Disease of UnceRtain Etiology (CKDu) in Agricultural Communities (CURE). The RSC will provide scientific expertise in planning clinical phenotyping and measures of renal function; will guide strategies for biological sampling and handling; and will provide needed clinical laboratory based measures and renal pathology. The RSC will also provide renal pathophysiologic expertise to propose approaches, novel measures (e.g., omics and molecular markers) and interpret discovery science to elucidate the cause or causes of CKDu. This collaborative research consortium will bring together a broad range of expertise and enable discovery science to understand the cause or causes of CKDu and disease progression. The Consortium will also work to identify potential therapeutic targets and public health interventions. The Consortium will consist of a Scientific Data Coordinating Center (SDCC), Field Epidemiology Sites (FES), a Renal Science Core (RSC), and the Human Health Exposure Analysis Resource (HHEAR). The

55








Amount


Consortium will work together to finalize ethical epidemiology research designs, execute common strategies for biological sampling and environmental assessment, apply the best analytic strategies for collected samples and data, and disseminate results to the global research and public health communities. The final design of the study, as determined by the Steering Committee, may significantly vary from individual applications. It is required that all funded sites fully abide with the final harmonized design set by the Consortium Steering Committee.

086094 Environmental Risks for Psychiatric Disorders: Biological Basis of Pathophysiology (R21 Clinical Trial Not Allowed)

National Institute of Environmental Health Sciences/NIH/DHHS

PAR-19-385 16-Nov-2020 400,000 USD

Contact Name Jonathan A. Hollander, Ph.D. Contact Telephone 984-287-3269



Synopsis

The purpose of this funding opportunity announcement (FOA) is to stimulate research to understand the biological basis by which environmental exposures alter brain and behavioral functioning to increase risk for psychiatric disorders with onset in late-childhood, adolescence or early adulthood. Applications should address either categorically defined psychiatric diagnoses and/or continuous traits expressed in the general population. Applicants are encouraged to propose studies that consider co-occurring psychiatric conditions and potential shared etiologies. It is anticipated that knowledge gained from the research supported by this FOA will inform the development of improved intervention, prevention and/or therapeutic strategies. This FOA will use the NIH Exploratory/Developmental Research Grant (R21) award mechanism and runs in parallel with another FOA, PAR-19-386, which encourages applications under the R01 mechanism.

086096 Environmental Risks for Psychiatric Disorders: Biological Basis of Pathophysiology (R01 Clinical Trial Not Allowed)


PAR-19-386 16-Nov-2020 2,000,000 USD

Contact Name Jonathan A. Hollander, Ph.D. Contact Telephone 984-287-3269


56










Amount



Synopsis

The purpose of this funding opportunity announcement (FOA) is to stimulate research to understand the biological basis by which environmental exposures alter brain and behavioral functioning to increase risk for psychiatric disorders with onset in late-childhood, adolescence or early adulthood. Applications should address either categorically defined psychiatric diagnoses and/or continuous traits expressed in the general population. Applicants are encouraged to propose studies that consider co-occurring psychiatric conditions and potential shared etiologies. It is anticipated that knowledge gained from the research supported by this FOA will inform the development of improved intervention, prevention and/or therapeutic strategies. This FOA will use the NIH Research Project Grant (R01) award mechanism and runs in parallel with another FOA, PAR-19-385, which encourages applications under the R21 mechanism.

097190 RFA-ES-20-015 -- NIEHS Research Intensive Short Courses and Educational Opportunities (NIEHS RISE) (R25 - Clinical Trial Not Allowed)


RFA-ES-20-015 30-Oct-2020 [Optional][LOI/Pre-App]

1,000,000 USD

Contact Name Amanda E. Garton, Sc.M., M.S.P.P. Contact Telephone 984-287-3260



Deadline Dates (ALL) 30-Oct-2020 [Optional][LOI/Pre-App], 30-Nov-2020 , 29-Oct-2021 [Optional][LOI/Pre-App], 29-Nov-2021 , 28-Oct-2022 [Optional][LOI/Pre-App], 28-Nov-2022

Synopsis

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on: Courses for Skills Development The intent of this announcement is to encourage applications to develop and conduct short-term research education activities with the goal of improving knowledge and skills needed to conduct environmental health research. Short courses submitted under this FOA are expected to include relevant intensive hands-on training in environmental health science topics. In addition to in-person instruction, courses that incorporate innovative or novel education models, such as project-based learning or virtual instruction, are encouraged.

095765 RFA-ES-20-001 -- Collaborative Centers in Children's Environmental National Institute of RFA-ES-20-001 23-Oct-2020 2,500,000

57






https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-20-015.html




Amount


Health Research and Translation (P2C Clinical Trial Optional) Environmental Health Sciences/NIH/DHHS

[Optional][LOI/Pre-App]

USD

Contact Name Kimberly Gray, PhD Contact Telephone 984-287-3262



Synopsis

To accelerate the movement of research findings to action, NIEHS invites grant applications from institutions/organizations that propose to build a Collaborative Center in Children's Environmental Health Research and Translation (CEHRT Center). Centers are charged with developing effective strategies to translate key children's environmental health (CEH) research findings to relevant stakeholders in the community, academia and practice. The overall goal of this FOA is the creation of a national network of children's environmental health translation centers. Through external collaboration with the children's environmental health community, Centers will protect and improve children’s health by developing and testing new scientific questions and public health interventions/strategies with an eye towards translation; and mentoring a pipeline of new investigators interested in translational CEH. CEHRT centers will serve as leaders in CEH translational research and research methodology development, with a focus on creating actionable steps to move evidence-informed biomedical, behavioral, psychosocial, environmental research findings in children's environmental health to the wider community. The collective collaborative center program will also serve as a national research resource to support response efforts to emerging environmental exposures affecting children.

081424 Environmental Influences on Aging: Effects of Extreme Weather and Disaster Events on Aging Populations (R01 Clinical Trial Optional)



Contact Name Symma Finn, PhD Contact Telephone 984-287-3259


Program URL Link to program URL Deadline Dates (ALL) 09-Nov-2020 , 08-Mar-2021

58










Amount


Synopsis

The purpose of this funding opportunity announcement is to advance our understanding of the impact of extreme weather and disaster events in aging human populations. Together with the companion FOA (PAR- 19-XXX ) that focuses on underlying mechanisms of aging utilizing animal models, these two FOAs will help to explicate the behavioral, biological, and socioecological processes that occur during extreme weather or disaster events and that affect aging processes. Through the integration of the population studies and the companion mechanistic studies FOA, the ultimate goal is to improve the health and well-being of older adults via increased knowledge about extreme weather and disaster preparedness, response, and recovery.

077237 RFA-ES-18-007 -- Virtual Consortium for Translational/Transdisciplinary Environmental Research (ViCTER) (R01 Clinical Trial Optional)


RFA-ES-18-007 01-Nov-2020 [Optional][LOI/Pre-App]

1,200,000 USD

Contact Name Jonathan A. Hollander, PhD Contact Telephone 984-287-3269



Synopsis

National Institute of Environmental Health Sciences (NIEHS) invites applications to foster and promote early-stage transdisciplinary collaborations and/or translational research efforts among fundamental (technology and mechanism oriented), clinical (patient-oriented) and population-based researchers in the environmental health field. The newly established collaborative teams will come together in common interest to investigate potential linkages between human health and one or more environmental stressor(s). The ViCTER program is intended to support innovative high-risk, high-reward cross-disciplinary and/or translational research projects that are more difficult to achieve in a typical R01 application. Collaboration among investigators at different institutions through a virtual consortium arrangement are encouraged. This FOA will use the NIH Research Project (R01) award mechanism.

084593 RFA-ES-19-011 -- Mechanism for Time-Sensitive Research Opportunities in Environmental Health Sciences (R21 Clinical Trial Not Allowed)


RFA-ES-19-011 01-Sep-2020 275,000 USD

Contact Name Martha I. Barnes, MS Contact Telephone 919-541-3335

59











Amount




Deadline Dates (ALL) 01-Sep-2020 , 01-Oct-2020 , 02-Nov-2020 , 01-Dec-2020 , 04-Jan-2021 , 01-Feb-2021 , 01-Mar-2021 , 01-Apr-2021 , 03-May-2021 , 01-Jun-2021 , 01-Jul-2021 , 02-Aug-2021 , 01-Sep-2021 , 01-Oct-2021 , 01-Nov-2021 , 01-Dec-2021 , 03-Jan-2022 , 01-Feb-2022 , 01-Mar-2022 , 01-Apr-2022 , 02-May-2022 , 01-Jun-2022 , 01-Jul-2022 , 01-Aug-2022 , 01-Sep-2022 , 03-Oct-2022

Synopsis

This funding opportunity announcement (FOA) is intended to support novel environmental health research in which an unpredictable event or policy change provides a limited window of opportunity to collect human biological samples or environmental exposure data. The primary motivation of the FOA is to understand the consequences of natural and human-made disasters, emerging environmental public health threats, and policy changes in the U.S. and abroad. A distinguishing feature of an appropriate study is the need for rapid review and funding, substantially shorter than the typical NIH grant review/award cycle, for the research question to be addressed and swiftly implemented. The shortened timeframe will be achieved by more frequent application due dates and expediting peer review, council concurrence and award issuance. The entire cycle, from submission to award, is expected to be within 3-4 months.

087256 RFA-MH-20-510 -- Laboratories to Optimize Digital Health (R01 Clinical Trial Required)

National Institute of Mental Health/NIH/DHHS RFA-MH-20-510 02-Nov-2020 Not

Specified

Contact Name Adam Haim, Ph.D. Contact Telephone 301-435-3593


Program URL Link to program URL Deadline Dates (ALL) 02-Nov-2020 , 01-Jul-2021 , 01-Mar-2022

Synopsis

NIMH seeks applications for innovative research projects to test strategies to increase the reach, efficiency, effectiveness, and quality of digital mental health interventions which may impact mental health outcomes, including suicide behaviors and serious mental illness. This Funding Opportunity Announcement (FOA) is intended to support the development of digital health test beds that leverage well-established digital mental health platforms and infrastructure to rapidly refine and optimize existing evidence-based digital health interventions and to conduct clinical trials testing digital mental health interventions that are statistically powered to provide a definitive answer regarding the intervention's effectiveness.

077700 RFA-MH-19-242 -- Computational Approaches for Validating National Institute of Mental RFA-MH-19-242 20-Oct-2020 Not

60






https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-20-510.html




Amount


Dimensional Constructs of Relevance to Psychopathology (R01 Clinical Trial Optional)

Health/NIH/DHHS [Optional][LOI/Pre-App]

Specified

Contact Name Michele Ferrante, Ph.D. Contact Telephone 301-435-6782



Synopsis

National Institute of Mental Health (NIMH) invites applications for research projects that will use computational approaches to test the validity of dimensional constructs in the NIMH Research Domain Criteria matrix (or similar constructs based on comparable criteria). Some elements of the RDoC matrix have been updated since its first release, but a thorough data-driven validation that broadly explores, compares, and validates the constructs within the matrix has not been performed. This FOA seeks research that addresses the following questions: do the different domains of behavior segregate from each other? How much do they rely on distinct versus overlapping neural circuits? What are the relationships between domains, constructs and subordinate sub-constructs, both in terms of their correlational structure and their underlying neural circuitry? By answering these questions, proposed research projects will test integrative models of functioning and identify dysregulation in psychopathology-related mechanisms that may cut across traditional diagnostic categories and may change over time. This FOA seeks to promote projects where the computational and the experimental components are well integrated. The ultimate goal is to advance translational research that will identify novel classification approaches and/or treatment targets, and lead to more effective and timely interventions for serious mental illnesses. This FOA will use the NIH Research Project (R01) award mechanism.

097372 RFA-RM-20-017-- Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa): Ethical, Legal, and Social Implications Research (U01 – Clinical Trial Not Allowed)

National Institute of Mental Health/NIH/DHHS RFA-RM-20-017


2,000,000 USD

Contact Name James D. Churchill, Ph.D. Contact Telephone 301-443-3621



61












Amount


Deadline Dates (ALL) 02-Nov-2020 [Optional][LOI/Pre-App], 01-Dec-2020

Synopsis

The purpose of this funding opportunity announcement (FOA) is to support research on the Ethical, Legal, and Social Implications (ELSI) associated with a new program entitled Harnessing Data Science for Health Discovery and Innovation in Africa (DS-I Africa). The goal of DS-I Africa is to spur new health discoveries and catalyze innovation in healthcare, public health, and health research on the continent through application of data science. A primary goal of this FOA is to explore the ELSI issues impacting data science for health research from an African perspective and contribute to the policy discussions of such on the continent. Through this FOA and related announcements, it is expected that ELSI research efforts will be fully embedded and integrated components of the consortia of activities supported through related DS-I Africa FOAs. Supported DS-I Africa ELSI awardees will work closely with DS-I Africa coordinating centers and DS-I Africa research hubs in considering how to dynamically address core ethical issues that may arise as the larger research projects uncover additional opportunities in this space. The cooperative agreements made through this FOA must be direct awards to African institutions, but applications can include partnerships with organizations from other areas.

076856 RFA-MH-19-240 -- Computationally-Defined Behaviors in Psychiatry (R21 Clinical Trial Optional)

National Institute of Mental Health/NIH/DHHS RFA-MH-19-240


275,000 USD

Contact Name Michele Ferrante, Ph.D. Contact Telephone 301-435-6782



Synopsis

National Institute of Mental Health (NIMH) invites applications for research projects that will apply computational approaches to develop parametrically detailed behavioral assays across mental-health relevant domains of function. These projects should focus on behavior in humans and test computational models in healthy subjects. NIMH is particularly interested in the study of behavioral measures, models, and parameters that have the potential for back-translation from humans to animals, especially for pre-clinical therapeutics development, and/or in models that have the potential to be extended to clinical populations. This program will use the NIH Exploratory/Developmental (R21) grant mechanism.

077849 RFA-NS-19-011--NIH Blueprint Diversity Specialized Predoctoral to Postdoctoral Advancement in Neuroscience (D-SPAN) Award (F99/K00 Independent Clinical Trial Not Allowed)

National Institute of Neurological Disorders and Stroke/NIH/DHHS RFA-NS-19-011


Not Specified

62










Amount


Contact Name Michelle Jones-London, PhD Contact Telephone 301-451-7966


Program URL Link to program URL Deadline Dates (ALL) 15-Nov-2020 [Optional][LOI/Pre-App], 15-Dec-2020 , 16-Mar-2021 [Optional][LOI/Pre-App], 15-Apr-2021

Synopsis

The purpose of the NIH Blueprint Diversity Specialized Predoctoral to Postdoctoral Advancement in Neuroscience (D-SPAN) Award is to support a defined pathway across career stages for outstanding graduate students from diverse backgrounds, including those from groups underrepresented in biomedical and behavioral sciences. This two-phase award will facilitate completion of the doctoral dissertation and transition of talented graduate students to strong neuroscience research postdoctoral positions, and will provide career development opportunities relevant to their long-term career goal of becoming independent neuroscience researchers. This Funding Opportunity Announcement (FOA) does not allow applicants to propose to lead an independent clinical trial, but does allow applicants to propose research experience in a clinical trial led by a sponsor or co-sponsor

63


https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-19-011.html

National Science Foundation (NSF) Funding Opportunities

SPIN ID Program Title Sponsor Name Sponsor Number

Deadline Date

Funding Amount

National Science Foundation (NSF) Funding Opportunities: Nov 2020

090458 Historically Black Colleges and Universities Undergraduate Program (HBCU-UP)

National Science Foundation 20-559 08-Sep-2020 [LOI/Pre-

App] Not Specified

Contact Name Claudia Rankins Contact Telephone 703-292-8109

Contact Email [email protected] Sponsor Website Link to sponsor website

Program URL Link to program URL Deadline Dates (ALL) 08-Sep-2020 [LOI/Pre-App], 06-Oct-2020 , 12-Nov-2020 , 22-Mar-2022 [LOI/Pre-App], 22-Nov-2022

Synopsis HBCU-UP provides awards to strengthen STEM undergraduate education and research at HBCUs.

090168 ADVANCE: Organizational Change for Gender Equity in STEM Academic Professions (ADVANCE)

National Science Foundation 20-554 03-Nov-2020 [LOI/Pre-

App] Not Specified

Contact Name Jessie DeAro Contact Telephone 703-292-5350


Program URL Link to program URL Deadline Dates (ALL) 03-Nov-2020 [LOI/Pre-App], 04-Feb-2021 , 04-Feb-2021 , 22-Apr-2021 [LOI/Pre-App], 07-Oct-2021

Synopsis

The NSF ADVANCE program contributes to the National Science Foundation's goal of a more diverse and capable science and engineering workforce. In this solicitation, the NSF ADVANCE program seeks to build on prior NSF ADVANCE work and other research and literature concerning gender, racial, and ethnic equity. The NSF ADVANCE program goal is to broaden the implementation of evidence-based systemic change strategies that promote equity for STEM faculty in academic workplaces and the academic profession. The NSF ADVANCE program provides grants to enhance the systemic factors that support equity and inclusion and to mitigate the systemic factors that create inequities in the academic profession and workplaces. Systemic (or organizational) inequities may exist in areas such as policy and practice as well as in organizational culture and climate. For example, practices in academic departments that result in the inequitable allocation of service or teaching assignments may impede research productivity, delay advancement, and create a culture of differential treatment and rewards. Similarly, policies and procedures that do not mitigate implicit bias in hiring, tenure, and promotion decisions could lead to women and racial and ethnic minorities being evaluated less favorably, perpetuating historical under-participation in

64




https://www.grants.gov/web/grants/view-opportunity.html?oppId=325437

https://www.nsf.gov/pubs/2020/nsf20559/nsf20559.htm








Deadline Date

Funding Amount


STEM academic careers and contributing to an academic climate that is not inclusive.

098009 NSF/VMware Partnership on the Next Generation of Sustainable Digital Infrastructure (NGSDI)

National Science Foundation 20-594 04-Nov-2020 3,000,000 USD

Contact Name Erik Brunvand Contact Telephone 703-292-2767



Synopsis

The goal of this joint solicitation between NSF and VMware is to foster novel, transformative research in fundamental and systematic approaches that bring dramatic increases in the environmental sustainability of the Digital Infrastructure leading to practical methodologies and tools. The Digital Infrastructure is broadly defined as the totality of software, hardware, and the methods for managing them for the purpose of efficient computation. This research includes, but is not limited to, computer software and systems; management of distributed software, the Digital Infrastructure, and data center power sourcing; and resource allocation and scheduling. Critical to initiating such research is to set its objectives through the definition of novel metrics and benchmarks that capture the sustainability challenges of all components in the entire computation chain. The program also aims to support a research community committed to advancing research and education at the confluence of management technologies for software, hardware and power for Sustainable Digital Infrastructure, and to transition research findings into practice. A new generation of innovation would build on many recent advances such as passive and active measurements, statistical analysis and inference, learning for automated control and complex optimization, workload isolation and management, agile development, convergence of development and production environments, and architecture-optimized language translation.

098242 Harnessing the Data Revolution: Coordination Hub (HDR Central) National Science Foundation 20-600 12-Nov-2020 2,000,000 USD

Contact Name Amy Walton Contact Telephone 703-292-4538


65











Deadline Date

Funding Amount



Synopsis

NSF's Harnessing the Data Revolution (HDR) Big Idea is a national-scale activity to enable new modes of data-driven discovery that will allow fundamental questions to be asked and answered at the frontiers of science and engineering. In 2019, the HDR Big Idea launched three parallel efforts in pursuit of these aims: Institutes for Data-Intensive Research in Science and Engineering (I-DIRSE), HDR: Transdisciplinary Research In Principles Of Data Science Phase I (HDR TRIPODS Phase I), and Data Science Corps (DSC). To engage participants across these efforts and amplify their impacts, this program solicits proposals for a nationwide HDR Coordination Hub, called HDR Central. The overarching purpose of HDR Central will be to increase the impact of the HDR Big Idea by supporting coordination and communication among all HDR projects, and by sharing HDR efforts and outcomes with the public.

096215 Dynamics of Integrated Socio-Environmental Systems (DISES) National Science Foundation 20-579 16-Nov-2020 1,600,000 USD

Contact Name Elizabeth R. Blood Contact Telephone 703-292-4349



Synopsis

The DISES Program supports research projects that advance basic scientific understanding of integrated socio-environmental systems and the complex interactions (dynamics, processes, and feedbacks) within and among the environmental (biological, physical and chemical) and human ("socio") (economic, social, political, or behavioral) components of such a system. The program seeks proposals that emphasize the truly integrated nature of a socio-environmental system versus two discrete systems (a natural one and a human one) that are coupled. DISES projects must explore a connected and integrated socio-environmental system that includes explicit analysis of the processes and dynamics between the environmental and human components of the system. PIs are encouraged to develop proposals that push conceptual boundaries and build new theoretical framing of the understanding of socio-environmental systems. Additionally, we encourage the exploration of multi-scalar dynamics, processes and feedbacks between and within the socio-environmental system.

097293 Ecology and Evolution of Infectious Diseases (EEID) National Science Foundation 20-585 18-Nov-2020 Not Specified

66









Deadline Date

Funding Amount


Contact Name Katharina Dittmar Contact Telephone 703-292-7799



Synopsis

The multi-agency Ecology and Evolution of Infectious Diseases program supports research on the ecological, evolutionary, and social drivers that influence the transmission dynamics of infectious diseases. The central theme of submitted projects must be the quantitative or computational understanding of pathogen transmission dynamics. The intent is discovery of principles of infectious disease transmission and testing mathematical or computational models that elucidate infectious disease systems. Projects should be broad, interdisciplinary efforts that go beyond the scope of typical studies. They should focus on the determinants and interactions of transmission among any host species, including but not limited to humans, non-human animals, and/or plants. This includes, for example, the spread of pathogens; the influence of environmental factors such as climate; the population dynamics and genetics of reservoir species or hosts; the feedback between ecological transmission and evolutionary dynamics; and the cultural, social, behavioral, and economic dimensions of pathogen transmission. Research may be on zoonotic, environmentally-borne, vector-borne, or enteric pathogens of either terrestrial or aquatic systems and organisms, including diseases of animals and plants, at any scale from specific pathogens to inclusive environmental systems. Proposals for research on disease systems of public health concern to developing countries are strongly encouraged, as are disease systems of concern in agricultural systems. Investigators are encouraged to develop the appropriate multidisciplinary team, including for example, anthropologists, modelers, ecologists, bioinformaticians, genomics researchers, social scientists, economists, oceanographers, mathematical scientists, epidemiologists, evolutionary biologists, entomologists, parasitologists, microbiologists, bacteriologists, virologists, pathologists or veterinarians, with the goal of integrating knowledge across disciplines to enhance our ability to predict and control infectious diseases.

097005 Ecology and Evolution of Infectious Diseases (EEID) (Defunct) National Science Foundation 20-585 18-Nov-2020 Not Specified

Contact Name Katharina Dittmar Contact Telephone 703-292-7799


67








Deadline Date

Funding Amount



Synopsis

The multi-agency Ecology and Evolution of Infectious Diseases program supports research on the ecological, evolutionary, and social drivers that influence the transmission dynamics of infectious diseases. The central theme of submitted projects must be the quantitative or computational understanding of pathogen transmission dynamics. The intent is discovery of principles of infectious disease transmission and testing mathematical or computational models that elucidate infectious disease systems. Projects should be broad, interdisciplinary efforts that go beyond the scope of typical studies. They should focus on the determinants and interactions of transmission among any host species, including but not limited to humans, non-human animals, and/or plants. This includes, for example, the spread of pathogens; the influence of environmental factors such as climate; the population dynamics and genetics of reservoir species or hosts; the feedback between ecological transmission and evolutionary dynamics; and the cultural, social, behavioral, and economic dimensions of pathogen transmission. Research may be on zoonotic, environmentally-borne, vector-borne, or enteric pathogens of either terrestrial or aquatic systems and organisms, including diseases of animals and plants, at any scale from specific pathogens to inclusive environmental systems. Proposals for research on disease systems of public health concern to developing countries are strongly encouraged, as are disease systems of concern in agricultural systems. Investigators are encouraged to develop the appropriate multidisciplinary team, including for example, anthropologists, modelers, ecologists, bioinformaticians, genomics researchers, social scientists, economists, oceanographers, mathematical scientists, epidemiologists, evolutionary biologists, entomologists, parasitologists, microbiologists, bacteriologists, virologists, pathologists or veterinarians, with the goal of integrating knowledge across disciplines to enhance our ability to predict and control infectious diseases. The EEID competition broadly welcomes, but does not require, that projects include international collaborators.

68


Other Federal Funding Opportunities SPIN ID Program Title Sponsor Name Sponsor Number Deadline Date Funding Amount

Other Federal Funding Opportunities: Nov 2020

095028 Vision Research Program--Translational Research Award Department of the Army W81XWH-20-VRP-TRA 18-Nov-2020 1,000,000 USD

Contact Name Contact Telephone 301-682-5507



Synopsis

The vision of the VRP is to transform visual system trauma care for our Armed Forces and the Nation. Eye injury and visual dysfunction resulting from battlefield trauma affect a large number of Service members and Veterans. Surveillance data from the Department of Defense (DoD) indicate that eye injury accounts for approximately 15% of all injuries from battlefield trauma sustained during the wars in Afghanistan and Iraq, resulting in more than 182,000 ambulatory patients and 4,000 hospitalizations between 2000 and 2011. In addition, statistics from the Defense and Veterans Brain Injury Center show that through the first quarter of 2018, more than 380,000 Service members have been diagnosed with traumatic brain injury (TBI), which can have significant impact on vision even when there is no injury to the eye. Research sponsored by the Department of Veterans Affairs (VA) showed that as many as 75% of Service members who suffered a TBI have visual dysfunction, with some patients suffering vision loss and functional blindness. The FY20 VRP challenges the scientific community to design innovative research that will significantly advance the understanding, prevention, diagnosis, mitigation, and/or treatment of eye injury or visual dysfunction associated with military-relevant trauma. Research outcomes are expected to ultimately improve the care of Service members and Veterans as well as the American public.

095018 Vision Research Program--Investigator- Initiated Research Award Department of the Army W81XWH-20-VRP-IIRA 18-Nov-

2020 Not Specified




Synopsis The vision of the VRP is to transform visual system trauma care for our Armed Forces and the Nation. Eye injury and visual

69










dysfunction resulting from battlefield trauma affect a large number of Service members and Veterans. Surveillance data from the Department of Defense (DoD) indicate that eye injury accounts for approximately 15% of all injuries from battlefield trauma sustained during the wars in Afghanistan and Iraq, resulting in more than 182,000 ambulatory patients and 4,000 hospitalizations between 2000 and 2011. In addition, statistics from the Defense and Veterans Brain Injury Center show that through the first quarter of 2018, more than 380,000 Service members have been diagnosed with traumatic brain injury (TBI), which can have significant impact on vision even when there is no injury to the eye. Research sponsored by the Department of Veterans Affairs (VA) showed that as many as 75% of Service members who suffered a TBI have visual dysfunction, with some patients suffering vision loss and functional blindness. The FY20 VRP challenges the scientific community to design innovative research that will significantly advance the understanding, prevention, diagnosis, mitigation, and/or treatment of eye injury or visual dysfunction associated with military-relevant trauma. Research outcomes are expected to ultimately improve the care of Service members and Veterans as well as the American public.

095029 Vision Research Program--Focused Translational Team Science Award Department of the Army W81XWH-20-VRP-

FTTSA 18-Nov-2020 5,000,000 USD




Synopsis

The vision of the VRP is to transform visual system trauma care for our Armed Forces and the Nation. Eye injury and visual dysfunction resulting from battlefield trauma affect a large number of Service members and Veterans. Surveillance data from the Department of Defense (DoD) indicate that eye injury accounts for approximately 15% of all injuries from battlefield trauma sustained during the wars in Afghanistan and Iraq, resulting in more than 182,000 ambulatory patients and 4,000 hospitalizations between 2000 and 2011. In addition, statistics from the Defense and Veterans Brain Injury Center show that through the first quarter of 2018, more than 380,000 Service members have been diagnosed with traumatic brain injury (TBI), which can have significant impact on vision even when there is no injury to the eye. Research sponsored by the Department of Veterans Affairs (VA) showed that as many as 75% of Service members who suffered a TBI have visual dysfunction, with some patients suffering vision loss and functional blindness. The FY20 VRP challenges the scientific community to design innovative research that will significantly advance the understanding, prevention, diagnosis, mitigation, and/or treatment of eye injury or visual dysfunction associated with military-relevant trauma. Research outcomes are expected to ultimately improve the care of Service members and Veterans as well as the American public.

70







096251 Chronic Pain Management Research Program--Investigator-Initiated Research Award Department of the Army W81XWH-20-CPMRP-

IIRA 06-Nov-2020 Not Specified




Synopsis

Per the FY19 CPMRP Congressional appropriation, chronic pain is defined as pain that occurs on at least half the days for 6 months or more, and which can be caused by issues including, but not limited to, combat- and training-related physical or mental stress and trauma, migraines and chronic headaches, traumatic brain injury, arthritis, muscular-skeletal conditions, neurological disease, tick and vector-borne disease, other insect-transmitted or tropical disease, and cancer. The CPMRP encourages alignment of research projects with the Federal Pain Research Strategy for maximizing the impact of chronic pain research outcomes. Applications from investigators within the military Services and applications involving multidisciplinary collaborations among academia, industry, the military Services, the U.S. Department of Veterans Affairs (VA), and other Federal Government agencies are highly encouraged. The intent of the FY20 CPMRP IIRA is to support studies that have the potential to make significant advances in research, patient care, and/or quality of life in the FY20 CPMRP IIRA Focus Areas. IIRA applications may involve any phase of basic, translational, and clinically oriented research, including studies in animal models, research with human anatomical substances, and research with human subjects, as well as ancillary studies associated with an existing clinical trial; however, this award may not be used to conduct clinical trials. Multidisciplinary collaborations and innovative approaches are encouraged.

096253 Chronic Pain Management Research Program--Translational Research Award Department of the Army W81XWH-20-CPMRP-

TRA 06-Nov-2020 1,400,000 USD




71











Synopsis

Per the FY19 CPMRP Congressional appropriation, chronic pain is defined as pain that occurs on at least half the days for 6 months or more, and which can be caused by issues including, but not limited to, combat- and training-related physical or mental stress and trauma, migraines and chronic headaches, traumatic brain injury, arthritis, muscular-skeletal conditions, neurological disease, tick and vector-borne disease, other insect-transmitted or tropical disease, and cancer. The CPMRP encourages alignment of research projects with the Federal Pain Research Strategy for maximizing the impact of chronic pain research outcomes. Applications from investigators within the military Services and applications involving multidisciplinary collaborations among academia, industry, the military Services, the U.S. Department of Veterans Affairs (VA), and other Federal Government agencies are highly encouraged. The intent of the FY20 CPMRP TRA is to support translational research that will accelerate the movement of evidence-based ideas in chronic pain management research into clinical applications, such as healthcare products, technologies, clinical practice guidelines, and/or models of care. TRA applications should explain how the proposed work will inform the development, refinement, and/or revision of existing standards of care, recommendations, or guidelines for managing chronic pain. Studies evaluating opioid-based therapeutic interventions are not allowed.

057446 AHRQ Conference Grant Program (R13) Agency for Healthcare Research and Quality/DHHS PA-16-453 01-Nov-

2020 150,000 USD

Contact Name Linda Franklin Contact Telephone 301-427-1904


Program URL Link to program URL Deadline Dates (ALL) 01-Nov-2020 , 01-Feb-2021 , 01-May-2021 , 01-Aug-2021 , 01-Nov-2021

Synopsis

Agency for Healthcare Research and Quality (AHRQ) announces its interest in supporting conferences through the AHRQ Single Year and Multiple Year Conference Grant Programs (R13). AHRQ seeks to support conferences that help to further its mission to produce evidence to make health care safer, higher quality, more accessible, equitable and affordable, and to work with HHS and other partners to make sure that the evidence is understood and used (http://www.ahrq.gov/funding/policies/foaguidance/index.html. This FOA will use the conference grant (R13) award mechanism.

72



http://grants.nih.gov/grants/guide/pa-files/PA-16-453.html

Non Federal Funding Opportunities SPIN ID Program Title Sponsor Name Sponsor Number Deadline Date Funding Amount

Non Federal Funding Opportunities: Nov 2020

013641 ENTELLIGENCE Young Investigators Award Program Actelion Pharmaceuticals US, Inc. 02-Nov-2020 [LOI/Pre-

App] 100,000 USD


Contact Email Sponsor Website Link to sponsor website

Program URL Link to program URL Deadline Dates (ALL) 02-Nov-2020 [LOI/Pre-App], 01-Feb-2021

Synopsis

ENTELLIGENCE is a program designed for basic science, translational and clinical research in the field of cardiopulmonary medicine. The ENTELLIGENCE program provides opportunities for individual young investigators to promote quality medical care and enhance patients' lives by supporting research (basic science, translational and clinical research) in the area of pulmonary hypertension (PH) related to expanding our knowledge of the pathways involved in pulmonary vascular pathobiology and ultimately, to improve treatment for patients with pulmonary hypertension. ENTELLIGENCE provides individual grants of up to $100,000 to qualified investigators to conduct research via a 12-month mentored grant.

053768 Paul Silver Enrichment Award Alport Syndrome Foundation, Inc. 20-Nov-2020 3,000 USD




Synopsis The Paul Silver Enrichment Award is given to young people affected by Alport syndrome achieve one of their own

73


https://www.entelligencemd.org/program_overview

https://www.entelligencemd.org/submitting_an_application



http://alportsyndrome.org/

https://alportsyndrome.org/connect/paul-silver-enrichment-award/



goals. It can be used to complete a project or pursue an activity that will enhance the applicant’s life.

055305 Program to Accelerate Clinical Trials (PACT) Alzheimer's Drug Discovery Foundation 09-Oct-2020 [LOI/Pre-

App] 3,000,000 USD



Program URL Link to program URL Deadline Dates (ALL) 09-Oct-2020 [LOI/Pre-App], 06-Nov-2020

Synopsis

The true test for new Alzheimer's drugs is in human clinical trials. Numerous treatments for Alzheimer's disease have been shown to be safe and to have some positive effect when tested in animal models of Alzheimer's disease. However, many of these potentially successful treatments have not been brought to human trials because of the increased cost and risk at this stage of research. The goal of this Request for Proposals (RFP) is to increase the number of innovative treatments tested in humans for Alzheimer's disease, related dementias, and cognitive aging.

055304 Drug Development Program Alzheimer's Drug Discovery Foundation 09-Oct-2020 [LOI/Pre-

App] 600,000 USD

Contact Name Alessio Travaglia, PhD, Scientific Program Officer Contact Telephone 212-901-7998



Synopsis The focus of this request for proposals is to develop therapeutics for Alzheimer's disease and related dementias. This

74



https://www.alzdiscovery.org/research-and-grants/funding-opportunities

https://www.alzdiscovery.org/research-and-grants/funding-opportunities/pact




https://www.alzdiscovery.org/research-and-grants/funding-opportunities/drug-development-program



RFP focuses on building preclinical evidence in animal models and on advancing lead molecules to the clinical candidate selection stage. The proposed studies should have a high probability of reaching IND-enabling studies within two years.

059477 Neuromarkers and CSF Biomarker Development Program Alzheimer's Drug Discovery Foundation 09-Oct-2020 [LOI/Pre-

App] Not Specified

Contact Name Meriel Owen, PhD, Scientific Program Officer Contact Telephone 212-901-7992



Synopsis

Given the pathological heterogeneity of Alzheimer's disease and related dementias, new biomarkers are needed to more accurately characterize specific underlying pathophysiology. This RFP seeks to support the development of CSF and neuroimaging biomarkers for multiple contexts of use (see below) that include but are not limited to: Clearly demonstrate target engagement for novel therapeutics The development of biomarkers that can serve as measures of target engagement for novel targets such as neuroinflammation features (e.g. microglial activity, cytokine production, astrocytic activity), synaptic damage, metabolic activity, mitochondrial dysfunction, vascular health and epigenetic changes, among others, are of particular interest. High priority will be given to projects developing biomarkers that can be used in combination with therapies currently in development and serve as companion biomarkers. Detect signs of disease earlier and monitor progression We are seeking programs developing sensitive biomarkers that can detect disease earlier than currently available tests. This includes biomarkers that can predict and monitor conversion from cognitively healthy to mild cognitive impairment (MCI) or MCI to Alzheimer's disease. We also seek prognostic markers that can predict rates of cognitive decline. More accurately diagnose and distinguish between dementia subtypes Many types of dementias can present with similar clinical features, and patients often show overlapping pathologies. At present, it is challenging to distinguish between dementia subtypes. Biomarkers that can distinguish between subtypes and stratify patients in clinical trials are of high priority.

75



http://www.alzdiscovery.org/




061078 Request For Proposal: Prevention Beyond The Pipeline Alzheimer's Drug Discovery Foundation 09-Oct-2020 [LOI/Pre-

App] Not Specified

Contact Name Yuko Hara, PhD, Assistant Director, Aging and Alzheimer's Prevention Contact Telephone 212-901-7991



Synopsis The ADDF seeks to support prevention drug discovery not covered by most research funders or their current RFPs.

064786 Target Validation Pathfinder Grant Alzheimer's Research UK 11-Nov-2020 65,000 USD

Contact Name Contact Telephone 0300 111 5555



Synopsis The Target Validation Pathfinder Grant scheme provides funds for small, translational research projects that show potential for an application to the Dementia Consortium or collaboration with the ARUK Drug Discovery Alliance.

004969 Faculty Development Award American Academy of Allergy, Asthma, & Immunology 07-Sep-2020 [LOI/Pre-

App] 240,000 USD

Contact Name

76




https://www.alzdiscovery.org/research-and-grants/funding-opportunities/prevention-beyond-the-pipeline



https://www.alzheimersresearchuk.org/

https://www.alzheimersresearchuk.org/grants/target-validation-pathfinder-grant/





Sponsor Website Link to sponsor website Program URL Link to program URL

Deadline Dates (ALL) 07-Sep-2020 [LOI/Pre-App], 13-Nov-2020

Synopsis

The AAAAI Foundation is dedicated to support the development of junior faculty to further their careers in Allergy and Immunology, and to help create leaders and independent investigators by funding excellent research that will lead to the prevention and cure of asthma, allergic and immunologic disease. The award provides a total of $240,000 in funding, paid out to the awardee’s institution in six equal payments over a three-year period starting July 1, 2021.

085302 Research Award American Academy of Clinical Toxicology 01-Nov-2020 6,000 USD




Synopsis The goal of this grant program is to provide competitive funding for clinical research that encourages the development of new therapies and treatment and adds to the understanding of the principles and practice of clinical toxicology.

069414 Orthodontic Faculty Development Fellowship Awards: Business/Practice of Orthodontics

American Association of Orthodontists Foundation 13-Nov-2020 20,000

USD


77


https://www.aaaaifoundation.org/research

https://aaaai.planion.com/Z?Y79089YNY



http://www.clintox.org/grants

http://www.clintox.org/grants/aact-research-award







Synopsis

The Orthodontic Faculty Development Fellowship Awards (OFDFA) provide support to individuals engaged in orthodontic training leading to a Master of Science, Ph.D. or other higher degree, an orthodontic graduate involved in postdoctoral research projects, and junior full time faculty serving in an orthodontic department. Fellowship Awards are intended only for those committed to a career in orthodontic teaching and/or research.

069411 Biomedical Research Awards: Business/Practice of Orthodontics American Association of Orthodontists Foundation 13-Nov-2020 30,000

USD




Synopsis

The AAOF solicits investigator-initiated applications on a wide range of research topics pertaining to orthodontics and/or craniofacial biology. The BRA is designed to assist mid-career and senior faculty in the U.S. and Canada to conduct independent research activities. Such activities are critical for academic and faculty development in orthodontic graduate programs. BRA proposals are generally expected to be either (i) small, well-defined and self-contained studies leading to publications in professional or scientific journals or (ii) pilot and feasibility studies to generate preliminary data in preparation of larger grant proposals to NIH or other research funding organizations.

010661 Ephraim P. Engleman Endowed Resident Research Preceptorship American College of Rheumatology 02-Nov-2020 15,000

USD

78


https://www.aaofoundation.net/awards-program/about-the-aaof-awards-program

https://www.aaofoundation.net/common/pages/UserFile.aspx?fileId=1255376



https://www.aaofoundation.net/awards-program/about-the-aaof-awards-program

https://www.aaofoundation.net/common/pages/UserFile.aspx?fileId=1255376






Program URL Link to program URL Deadline Dates (ALL) 02-Nov-2020 , 01-Feb-2021 , 01-May-2021

Synopsis The Ephraim P. Engleman Endowed Resident Research Preceptorship will introduce residents to the specialty of rheumatology by supporting a full-time research experience.

000941 Innovative Basic Science Award (IBS) American Diabetes Association, Inc. 16-Nov-2020 345,000

USD

Contact Name Contact Telephone



Synopsis

These awards support basic research with novel and innovative hypotheses in any area relevant to the etiology or pathophysiology of diabetes and its complications that holds significant promise for advancing the prevention, cure or treatment of diabetes. Applications proposing high-risk projects with the potential for high-impact results are encouraged, as are studies that may not be sufficiently developed for traditional funding sources.

075993 Standard Research Grants American Foundation for Suicide Prevention 15-Nov-2020 100,000

USD

Contact Name

79


https://www.rheumresearch.org/funding-opportunities#Tab

https://www.rheumresearch.org/preceptorships



http://professional.diabetes.org/

https://professional.diabetes.org/meetings/core-program







Synopsis The American Foundation for Suicide Prevention (AFSP) provides grants for many different types of studies, including: psychiatry, medicine, psychology, genetics, epidemiology, neurobiology, sociology, nursing, social work, health services administration and many others.

096921 AGA-Takeda Pharmaceuticals Research Scholar Award in Inflammatory Bowel Disease

American Gastroenterological Association 09-Nov-2020 300,000

USD




Synopsis This award provides $100,000 per year for three years (totaling $300,000) to early-career faculty (i.e., investigator, instructor, research associate or equivalent) working toward an independent career in inflammatory bowel disease (IBD) research.

096920 AGA-Takeda Pharmaceuticals Research Scholar Award in Celiac Disease American Gastroenterological Association 09-Nov-2020 300,000

USD


80


https://afsp.org/our-work/research/grant-information/

https://www.datocms-assets.com/12810/1571746096-standard-research-policy-2019-1.doc




https://www.gastro.org/research-and-awards/research-awards/apply-for-awards

https://gastro.org/research-and-awards/research-awards/apply-for-awards/award/aga-takeda-pharmaceuticals-research-scholar-award-in-inflammatory-bowel-disease/






Synopsis

This award provides $100,000 per year for three years (totaling $300,000) to early-career faculty (i.e., investigator, instructor, research associate or equivalent) working toward an independent career in celiac disease research. Applicants performing any type of research (basic, translational, clinical) relevant to celiac disease are eligible to apply. Studies of non-celiac gluten sensitivity will be considered if their contribution to the overall understanding of celiac disease is clearly justified in the application.

010996 Research Scholar Awards (RSA) American Gastroenterological Association 09-Nov-2020 300,000

USD




Synopsis The AGA Research Scholar Award (RSA) provides $100,000 per year for three years (totaling $300,000) to early-career faculty (i.e., investigator, instructor, research associate or equivalent) working toward an independent career in digestive disease research.

010673 Clinical Scientist in Nephrology Fellowship Program American Kidney Fund 23-Nov-2020 160,000 USD

Contact Name

81


https://www.gastro.org/research-and-awards/research-awards/apply-for-awards

https://gastro.org/research-and-awards/research-awards/apply-for-awards/award/aga-takeda-pharmaceuticals-research-scholar-award-in-celiac-disease/



https://gastro.org/research-and-awards/apply-for-awards/

https://gastro.org/research-and-awards/research-awards/apply-for-awards/award/aga-research-scholar-award-rsa/







Synopsis

The American Kidney Fund Clinical Scientist in Nephrology (CSN) fellowship program funds researchers whose work is designed to improve diagnosis, treatment and outcomes for patients living with chronic kidney disease (CKD) and has promoted clinical research in nephrology. CSN fellows conduct prevention and outcomes research while receiving advanced training in essential skills such as medical ethics, biostatistics and epidemiology. The maximum level of funding of $80,000 per year shall be used principally to support the candidate and his or her career development.

033877 Research Grant American Nephrology Nurses' Association 15-Nov-2020 15,000

USD




Synopsis The American Nephrology Nurses' Association provides a research grant to members for investigations in nephrology, transplantation, or related therapies.

033878 Evidence-Based Practice Project Grants American Nephrology Nurses' Association 31-Aug-2020

[Optional][LOI/Pre-App] 5,000 USD

Contact Name

82


https://www.kidneyfund.org/

https://www.kidneyfund.org/training/clinical-scientist-in-nephrology/



https://www.annanurse.org/

https://www.annanurse.org/professional-development/grants-and-awards/educational-scholarships-grants






Deadline Dates (ALL) 31-Aug-2020 [Optional][LOI/Pre-App], 15-Nov-2020

Synopsis Evidence-Based Practice Project Grants are offered to fund qualified nephrology nurses’ work to translate research into practice in support of developing evidence-based nephrology nursing practice and demonstrating the value of nephrology nursing in improving patient outcomes.

042268 Intervention Research Grant Program American Occupational Therapy Foundation 31-Aug-2020 [LOI/Pre-

App] 50,000 USD



Program URL Link to program URL Deadline Dates (ALL) 31-Aug-2020 [LOI/Pre-App], 30-Nov-2020

Synopsis The American Occupational Therapy Foundation (AOTF) awards Intervention Research Grants (IRG) as part of its mission to advance the science of occupational therapy to support people's full participation in meaningful life activities. One year non-renewable proposals for up to $50K (including indirect costs) will be considered.

085837 Health Services Research Grant American Occupational Therapy Foundation 31-Aug-2020 [LOI/Pre-

App] Not Specified


83


https://www.annanurse.org/

https://www.annanurse.org/professional-development/research/grants-and-awards



https://www.aotf.org/Grants/Intervention-Research-Grant

https://www.aotf.org/Portals/0/Images/Research%20Docs/IRG%20RFA%20AOTF%202020-2021.pdf?ver=OHUh9zBNn-h3Jyek5_qH4g%3d%3d






Synopsis

The American Occupational Therapy Foundation (AOTF) awards Health Services Research Grants as part of its mission to advance the science of occupational therapy to support people's full participation in meaningful life activities. Grants are targeted to principal investigators who do not currently have substantial extramural research awards as an independent principal investigator (e.g., NIH, R01, PCORI, Research Program Project Grant, Veterans Administration Merit Award, and Field-Initiated Project).

085834 Implementation Research Grant American Occupational Therapy Foundation 31-Aug-2020 [LOI/Pre-

App] Not Specified




Synopsis

The American Occupational Therapy Foundation (AOTF) awards Implementation Research (IR) Grants as part of its mission to advance the science of occupational therapy to support people's full participation in meaningful life activities. The IR grant specifically supports research that is focused on helping occupational therapists take evidence-informed practice from theory to reality in their practice setting. This research grant develops and evaluates the processes used to implement, sustain, and or scale-up evidence-based practice into routine care with an end goal to improve the quality and effectiveness of care.

032657 ASH Bridge Grant Program American Society of Hematology 01-Nov-2020 150,000

84


https://www.aotf.org/

https://www.aotf.org/Grants/Health-Services-Research-Grant



https://www.aotf.org/

https://www.aotf.org/Grants/Implementation-Research-Grant




USD




Synopsis Each year, the American Society of Hematology grants 15 to 20 yearlong awards to ASH members who applied for an NIH R01 grant or equivalent and were scored but not funded. ASH Bridge Grants are intended to help sustain recipients' research and contribute to their retention in hematology investigation while they reapply.

021033 Minority Medical Student Award Program American Society of Hematology 15-Nov-2020 Not Specified



Program URL Link to program URL Deadline Dates (ALL) 15-Nov-2020 , 15-Jan-2021

Synopsis

The ASH Minority Medical Student Award Program (MMSAP) provides underrepresented minority medical students with an opportunity to conduct a research project under the supervision of an ASH member, receive guidance from a career-development mentor, gain valuable knowledge of hematology, and ultimately, advance their careers. As part of the ASH Minority Recruitment Initiative, the MMSAP aims to expand the program’s reach to the next generation of hematologists.

85


https://www.hematology.org/awards/career-enhancement-and-training/bridge-grant

https://www.hematology.org/awards/career-enhancement-and-training/bridge-grant/supported-research



https://www.hematology.org/awards

https://www.hematology.org/awards/medical-student/minority-medical-student-award-program



057151 Coagulation Research Grant Aniara Diagnostica 01-Nov-2020 10,000 USD




Synopsis Aniara Diagnostica's Coagulation Research Grant provides one $10,000 grant for established investigators (eg - faculty at an academic institution) and for students/trainees to do innovative coagulation/hematology research.

023279 Short-Term Research/Training Fellowship Asian Pacific Society of Respirology 30-Nov-2020 Not

Specified

Contact Name Contact Telephone +81-3-5684-3370



Synopsis

The APSR is funding a scholarship programme with the aims of: promoting science and research in respiratory medicine in the APSR region; supporting the exchange in the APSR region of young scientists and clinicians actively involved in respiratory medicine; and contributing to the development of research and science of respiratory medicine in the APSR region.

077691 Bayer Hemophilia Awards Program -- Basic Research Award Bayer Biological Products 30-Nov-2020 [LOI/Pre- 75,000

86



https://www.aniara.com/aniara-grant.html?

https://www.aniara.com/mm5/PDFs/Research_Grant_Application.pdf



http://www.apsresp.org/awards/index.html

http://www.apsresp.org/scholarships/2017/apsr01.html




App] USD



Program URL Link to program URL Deadline Dates (ALL) 30-Nov-2020 [LOI/Pre-App]

Synopsis The Bayer Hemophilia Awards Program demonstrates Bayer's commitment to the bleeding disorders community and to advancing the state of the art of hemophilia care. The basic research award will provide funds to undertake a basic research project in the bleeding disorders field.

077690 Bayer Hemophilia Awards Program -- Clinical Research Award Bayer Biological Products 30-Nov-2020 [LOI/Pre-App]

75,000 USD




Synopsis The Bayer Hemophilia Awards Program demonstrates Bayer's commitment to the bleeding disorders community and to advancing the state of the art of hemophilia care. The clinical research award will provide funds to undertake a clinical research project in the bleeding disorders field.

076601 Bayer Hemophilia Awards Program -- Fellowship Project Award Bayer Biological Products 30-Nov-2020 [LOI/Pre-App]

80,000 USD

87


http://www.bayer-hemophilia-awards.com/about_the_program/

http://www.bayer-hemophilia-awards.com/awards/



http://www.bayer-hemophilia-awards.com/about_the_program/








Synopsis The Bayer Hemophilia Awards Program (BHAP) offers the Fellowship Project Award, which is intended to facilitate the development of clinical and research expertise in the field of hemophilia for applicants who have completed medical training and have an interest in pursuing a career as a hemophilia clinician.

089251 Medical Education Grants Biogen, Inc. 01-Nov-2020 Not Specified




Synopsis Biogen provides funding to an eligible institution or organization to support independent medical educational activities for HCPs and researchers. Medical education may be accredited or non-accredited.

089255 General Grants Biogen, Inc. 01-Nov-2020 Not Specified


88


http://www.bayer-hemophilia-awards.com/index.php




https://grantsandgiving.biogen.com/content/gma-grants-office/en_us/gmsgo/grants/medical-education.html






Synopsis Biogen provides funding to an eligible institution or organization to support a program or project that does not fit any of the other defined grant categories.

089253 Professional & Scientific Development Grants Biogen, Inc. 01-Nov-2020 Not Specified




Synopsis Biogen provides funding to an eligible institution or organization to support training and development for medical professionals or researchers within Biogen’s therapeutic areas of interest.

045337 Travel Awards British Society for Immunology 01-Nov-2020 1,300 USD

Contact Name Sarah Green Contact Telephone +44 (0)20 3019 5901



89


https://grantsandgiving.biogen.com/content/gma-grants-office/en_us/gmsgo/grants/general-grant.html



https://grantsandgiving.biogen.com/content/gma-grants-office/en_us/gmsgo/grants/professional-scientific-development.html



https://www.immunology.org/

https://www.immunology.org/grants-and-prizes/travel-awards




Synopsis

The BSI will support the travel costs for members who wish to attend meetings and congresses, both domestic and international; or, for example, those who wish to visit laboratories for specific short-term activities, such as collaborative research, or in order to learn new techniques. Maximum awards are currently as follows: £500 for travel within the UK ; £700 for European travel and £1000 for rest of the World.

062141 Investigators in the Pathogenesis of Infectious Disease (PATH) Award Burroughs Wellcome Fund 13-Nov-2020 500,000 USD

Contact Name Victoria McGovern, Program Officer Contact Telephone 919-991-5112



Synopsis

This award provides $500,000 over a period of five years to support accomplished investigators at the assistant professor level to study pathogenesis, with a focus on the interplay between human and microbial biology, shedding light on how human and microbial systems are affected by their encounters. The awards are intended to give recipients the freedom and flexibility to pursue new avenues of inquiry, stimulating higher risk research projects that hold potential for significantly advancing understanding of how infectious diseases work and how health is maintained.

098717 Doctoral Research Award: Vanier Canada Graduate Scholarships Canadian Institutes of Health Research 03-Nov-2020 112,500

USD



90



https://www.bwfund.org/grant-programs/infectious-diseases

https://www.bwfund.org/grant-programs/infectious-diseases/investigators-in-pathogenesis-of-infectious-disease







Synopsis

The Vanier Canada Graduate Scholarships (Vanier CGS) program attracts and retains world-class doctoral students and helps establish Canada as a global centre of excellence in research and higher learning. CIHR categorizes health research in four broad themes: 1.Biomedical Research; 2.Clinical Research; 3.Health Services Research; 4.Social, Cultural, Environmental and Population Health Research.

058489 Technology Impact Award Cancer Research Institute, Inc. 16-Nov-2020 [LOI/Pre-App]

200,000 USD



Program URL Link to program URL Deadline Dates (ALL) 16-Nov-2020 [LOI/Pre-App], 15-Mar-2021

Synopsis The Cancer Research Institute Technology Impact Award provides seed funding of up to $200,000 to be used over 12 to 24 months to address the gap between technology development and clinical application of cancer immunotherapies.

019240 Fellowship in Mood, Anxiety and Related Disorders Columbia University 30-Nov-2020 Not Specified

Contact Name Steven P. Roose, M.D. Contact Telephone 212-543-5749


91

http://www.vanier.gc.ca/fr/home-accueil.html

https://www.researchnet-recherchenet.ca/rnr16/vwOpprtntyDtls.do?prog=3341&view=currentOpps&org=CIHR&type=EXACT&resultCount=25&sort=program&next=1&all=1&masterList=true



https://www.cancerresearch.org/scientists/fellowships-grants/impact-grants

https://www.cancerresearch.org/scientists/fellowships-grants/technology-impact-award







Synopsis The Department of Psychiatry at the Columbia University Medical Center offers a two- to three-year training fellowship in clinical and basic research on mood, anxiety and related disorders. It is supported by a NIMH grant, and offers didactic methodological and statistical training as well as a supervised research experience.

019242 Fellowship In Schizophrenia Research Columbia University 30-Nov-2020 Not Specified

Contact Name Jonathan A. Javitch, M.D., Ph.D. Contact Telephone 646-774-8600



Synopsis

The Department of Psychiatry at the Columbia University Medical Center offers a fellowship that focuses on research strategies, basic and clinical, related to schizophrenia and psychotic disorders. Supervised research, training in statistics and research methodology, and didactic seminars on schizophrenia comprise the two- to three-year program, which is supported by a National Institute of Mental Health (NIMH) grant.

085272 Syringe Access Program Grants Comer Foundation 01-Nov-2020 Not Specified



92

https://www.columbiapsychiatry.org/research/research-training

https://www.columbiapsychiatry.org/education-and-training/research-training/fellowship-mood-anxiety-and-related-disorders



https://www.columbiapsychiatry.org/research/research-training

https://www.columbiapsychiatry.org/education-and-training/research-training/fellowship-schizophrenia-research







Synopsis

The Comer Foundation provides support to harm reduction-centered syringe access programs (SAP) to improve the health and wellness of people affected by drug use. These programs provide free sterile syringes, education, and often community wraparound services to reduce transmission of HIV, hepatitis C and opioid overdose. Average single-year grants range from $2,500 to $20,000.

098484 Advanced Clinical Research Award for Diversity and Inclusion Conquer Cancer Foundation of ASCO 15-Oct-2020 [LOI/Pre-

App] 450,000 USD




Synopsis

The Advanced Clinical Research Award (ACRA) for Diversity and Inclusion is designed with the primary goal of increasing diversity in the oncology workforce and cancer research. Awards will be given to midcareer investigators who are members of racial and/or ethnic groups historically underrepresented in academic medicine and wish to conduct original breast cancer research not currently funded.

083322 Crohn's & Colitis Foundation/NASPGHAN IBD Young Investigator Award Crohn's & Colitis Foundation of America 05-Nov-2020 [LOI/Pre-

App] Not Specified


93

http://www.comerfamilyfoundation.org/

http://www.comerfamilyfoundation.org/syringe-access-program/grant-applicants.html



https://www.asco.org/research-guidelines/grants-awards/funding-opportunities

https://www.asco.org/research-guidelines/grants-awards/funding-opportunities/advanced-clinical-research-award





Program URL Link to program URL Deadline Dates (ALL) 05-Nov-2020 [LOI/Pre-App], 28-Jan-2021

Synopsis This three-year grant, in partnership with the NASPGHAN Foundation and the Crohn’s & Colitis Foundation, is available to research fellows or junior faculty. Applications must propose original clinical, translational, epidemiological, or basic scientific research related to pediatric inflammatory bowel disease.

000394 CFF/NIH-unfunded Grant Award Cystic Fibrosis Foundation 02-Nov-2020 250,000 USD




Synopsis

The mission of the Cystic Fibrosis Foundation (CFF) is to cure cystic fibrosis (CF) and to provide all people with the disease the opportunity to lead full, productive lives by funding research and drug development, promoting individualized treatment, and ensuring access to high-quality, specialized care. To achieve this mission, various types of awards are offered to support meritorious research in CF. CFF has developed its research program to complement work at the National Institutes of Health (NIH). Support from CFF, through various mechanisms, is intended to provide support for the development of sufficient preliminary data to make CF-related applications highly competitive in the NIH review process. However, as a result of funding constraints on the NIH, coupled with the growing interest in CF research, occasions arise in which highly meritorious grants are submitted to the NIH but not funded. In an effort to assure that all meritorious CF-related research is supported, CFF has developed the CFF/NIH-Unfunded Award mechanism to provide bridge funding.

94


https://naspghan.org/research/naspghan-foundation-grants/



https://www.cff.org/Research/Researcher-Resources/Awards-and-Grants/Research-Awards/CFF-NIH-Unfunded-Award/

https://www.cff.org/Our-Research/For-Researchers/Research-Grants/CFF-and-NIH-Unfunded-Grant-Guidelines.pdf



089449 Research Grants Daisy Foundation 09-Sep-2020 [LOI/Pre-App] 5,000 USD

Contact Name Bonnie Barnes Contact Telephone 707-996-7936


Program URL Link to program URL Deadline Dates (ALL) 09-Sep-2020 [LOI/Pre-App], 04-Nov-2020

Synopsis The Research Grant provides awards to qualified nurses carrying out clinical research studies that directly benefit patients and/or families involving treatment of cancer and auto-immune diseases.

001443 Evidence-based Practice (EBP) Grants Daisy Foundation 09-Sep-2020 [LOI/Pre-App] 2,000 USD

Contact Name Bonnie Barnes Contact Telephone 707-996-7936



Synopsis Evidence-based Practice (EBP) grants will be awarded to stimulate the use of patient-focused data and/or previously generated research findings to develop, implement and evaluate changes in nursing practice in treatment of patients with cancer and auto-immune diseases.

025152 Award for Cancers of the Esophagus and Stomach DeGregorio Family Foundation 03-Nov-2020 250,000 USD

95



https://www.daisyfoundation.org/

https://www.daisyfoundation.org/https%3A/www.daisyfoundation.org/researchebp-grants/j-patrick-barnes-grants-goals-guidelines



https://www.daisyfoundation.org/

https://www.daisyfoundation.org/https%3A/www.daisyfoundation.org/researchebp-grants/j-patrick-barnes-grants-goals-guidelines







Synopsis The DeGregorio Family Foundation for Gastric and Esophageal Cancer provides annual funding for research on gastroesophageal malignancies.

004728 Medical Dermatology Career Development Award Dermatology Foundation 15-Oct-2020 165,000 USD



Program URL Link to program URL Deadline Dates (ALL) 15-Oct-2020 , 01-Nov-2020

Synopsis

The Medical Dermatology Career Development Award This CDA provides funding for future intellectual leaders, educators, and clinical scholars in that aspect of the specialty that addresses severe dermatologic disease. The award fosters the careers of young dermatologists who will become the future role models and mentors for physicians diagnosing and treating complex skin disease.

003290 Physician Scientist Career Development Award Dermatology Foundation 15-Oct-2020 165,000 USD

Contact Name

96


https://www.degregorio.org/

https://www.degregorio.org/grant-process



https://www.dermatologyfoundation.org/rap/Default.asp

https://www.dermatologyfoundation.org/pdf/rap/2021/DF_RAP_Applicant_Instructions_2021.pdf






Deadline Dates (ALL) 15-Oct-2020 , 02-Nov-2020

Synopsis The Physician Scientist CDA supports the academic career of a physician scientist who is devoted to clinical dermatology, and assists in the transition from fellowship to established investigator. This award is intended for the academic investigator demonstrating significant creativity in clinically relevant research.

014221 Public Health Career Development Award Dermatology Foundation 15-Oct-2020 55,000 USD




Synopsis The Public Health Career Development Award supports the establishment and/or development of careers in public health.

093397 Medical Robotics for Contagious Diseases Challenge EPSRC UK-Robotics and Autonomous Systems (UK-RAS) Network

30-Sep-2020 [LOI/Pre-App]

Not Specified

Contact Name Claire Asher, UK-RAS Network Manager Contact Telephone

97


https://www.dermatologyfoundation.org/rap/




https://www.dermatologyfoundation.org/rap/






Program URL Link to program URL Deadline Dates (ALL) 30-Sep-2020 [LOI/Pre-App], 28-Oct-2020 , 06-Nov-2020

Synopsis The UK-RAS Network has announced a new Medical Robotics Challenge for Contagious Diseases.

059992 Translational Medicine Fellowship European Neuroendocrine Tumor Society 04-Nov-2020 46,800

USD

Contact Name Contact Telephone +49 (30) 450 553 096



Synopsis European Neuroendocrine Tumor Society (ENTS) invites applications for the Translational Medicine Fellowship Grant. The total grant amount for a two-year ENETS Translational Medicine Fellowship is Euro 40,000.

010950 General Request for Applications (RFA) Foundation for Prader-Willi Research 15-Sep-2020 [LOI/Pre-

App] 100,000 USD

Contact Name Jessica Bohonowych Contact Telephone 888-322-5487



98


https://www.ukras.org/

https://www.ukras.org/robotics-week/challenges/medical-robotics-for-contagious-diseases-challenge-2020/



https://www.enets.org/

https://www.enets.org/grants_and_awards.html



https://www.fpwr.org/grant-program

https://www.fpwr.org/request-for-applications



Deadline Dates (ALL) 15-Sep-2020 [LOI/Pre-App], 20-Nov-2020

Synopsis

The Foundation for Prader-Willi Research (FPWR), a nonprofit organization dedicated to supporting research to advance the understanding and treatment of Prader-Willi syndrome (PWS), announces the availability of funds to support innovative PWS research. FPWR is particularly interested in supporting projects that will lead to new treatments to alleviate the symptoms associated with PWS.

073959 Research Grants Program Gerber Foundation 15-Nov-2020 [LOI/Pre-App]

Not Specified



Program URL Link to program URL Deadline Dates (ALL) 15-Nov-2020 [LOI/Pre-App], 15-Feb-2021

Synopsis The Foundation’s mission focuses on infants and young children. Accordingly, priority is given to projects that improve the nutrition, care and development of infants and young children from the first year before birth to three years of age. Total grant size should be no more than roughly $20,000 (inclusive of direct costs).

061757 Warren Alpert Foundation Prize Harvard Medical School 03-Nov-2020 500,000 USD

Contact Name Edward Canton Contact Telephone 617-432-2116



99



http://www.gerberfoundation.org/focus-areas/

http://www.gerberfoundation.org/how-to-apply/



https://warrenalpert.org/prize

https://warrenalpert.org/online-nomination




Synopsis

The Warren Alpert Foundation Prize, in association with Harvard Medical School, recognizes and honors one or more scientists, physicians and researchers whose scientific achievements have led to the prevention, cure or treatment of human diseases or disorders, and/or whose research constitutes a seminal scientific finding that holds great promise of ultimately changing our understanding of or ability to treat disease.

005185 Call For Proposals Innovative Medicines Initiative (IMI) 05-Nov-2020 Not

Specified

Contact Name Contact Telephone +32 2 221 8181



Synopsis The Innovative Medicines Initiative (IMI) has launched its 20th and 21st calls for proposals.

084832 International Network for Orofacial Pain and Related Disorders Methodology (INfORM) Investigator Awards by Quintessence Publishing and Journal of Oral & Facial Pain and Headache

International Association for Dental Research 25-Oct-2020 Not

Specified

Contact Name Richard Ohrbach, Award Chairperson Contact Telephone 703-548-0066



100



https://www.imi.europa.eu/apply-funding/open-calls

https://www.imi.europa.eu/apply-funding/open-calls/imi2-call-20





https://www.iadr.org/

http://www.iadr.org/IADR/Awards/Scientific-Group-Awards/INfORM/Investigator-Awards



Synopsis

The International Network for Orofacial Pain and Related Disorders Methodology (INfORM), a consortium focused on clinical translational research (hereafter, International Network) in conjunction with Quintessence Publishing and Journal of Oral & Facial Pain and Headache, provides an award for early career clinical researchers/scientists. The awards will be given to investigators for an outstanding clinical or translational research abstract and project pertaining to Orofacial Pain and Related Conditions submitted to the IADR General Annual Session & Exhibition.

095169 Educational Grants -- Infectious Diseases (HIV/AIDS) Janssen Biotech, Inc. 15-Sep-2020 Not Specified



Program URL Link to program URL Deadline Dates (ALL) 15-Sep-2020 , 15-Nov-2020 , 15-Jan-2021 , 15-Mar-2021 , 15-May-2021

Synopsis

Janssen provides grants to support educational activities for healthcare providers, allied healthcare providers and patients. Priority is given for activities within Janssen’s areas of scientific interest that contribute to improved knowledge, practice and performance for healthcare providers and improved health outcomes for patients, including in the area of Infectious Diseases. Grants are available for: Continuing Medical Education (CE)/Non-Accredited Continuing Education (NCE); Fellowships; and Patient Education.

081724 Therapeutic Area Contributions - Infectious Diseases Program Janssen Pharmaceuticals, Inc. 30-Sep-2020 Not Specified



101



https://www.janssen.com/us/grants-and-giving/educational-grants/

https://pharmaedgrants.com/Janssen/Pages/Misc/LandingPage.aspx


https://www.janssen.com/us/grants-and-giving/charitable-contributions



Program URL Link to program URL Deadline Dates (ALL) 30-Sep-2020 , 15-Nov-2020

Synopsis

The sponsor makes charitable contributions to support therapeutic area initiatives. Applications are evaluated competitively with emphasis given to innovative programs with measurable outcomes that address disparities or unmet needs. The Infectious Diseases area of interest supports the following disease states: Hepatitis B; HIV / AIDS; Respiratory Infections; and Vaccines.

021422 Grant Programs - Medical Research Phase I Application Keck (W. M.) Foundation 01-Nov-2020 5,000,000 USD

Contact Name Heather Anderson, Program Coordinator Contact Telephone 213-680-3833



Synopsis The Medical Research Program seeks to support pioneering discoveries in medical research by funding the high-risk/high-impact work of leading researchers, laying the groundwork for new paradigms, technologies and discoveries that will save lives, provide innovative solutions, and add to our understanding of the world.

008012 Fellowships for Graduate Students at the Technion Lady Davis Fellowship Trust 30-Nov-2020 Not Specified

Contact Name Gabriela Laufmann Contact Telephone 972-2-651-2306


102

https://www.janssen.com/us/sites/www_janssen_com_usa/files/janssen_focus_areas_for_therapeutic_giving.pdf



http://www.wmkeck.org/

http://www.wmkeck.org/grant-programs/research



http://ldft.huji.ac.il/fellowships-information/technion-fellowships/general-information




Synopsis The Lady Davis Fellowship Trust was established to provide an opportunity for doctoral students from abroad, regardless of nationality, gender or field of scholarship to teach, study and participate in research in Israel at the Hebrew University in Jerusalem and at the Technion Institute of Technology in Haifa.

089679 https://www.lupusresearch.org/wp-content/uploads/2020/02/GTSA-RFA_FINAL3.pdf Lupus Research Alliance 01-Nov-2020 Not

Specified

Contact Name Teodora Staeva, Phd Contact Telephone 646-884-6090



Synopsis

The Lupus Research Alliance Global Team Science Awards will support interdisciplinary, collaborative, and highly synergistic projects that push the boundaries of innovation and bridge research and clinical efforts in lupus. The successful Teams will focus on unraveling human lupus heterogeneity by applying cutting-edge technologies to address critical questions that could bring about breakthroughs in lupus care, research or drug development.

012666 Endocrinology, Diabetes and Metabolism Fellowship (Florida) Mayo Clinic College of Medicine and Science 30-Nov-2020 Not

Specified

Contact Name Andrew Diaz, Endocrinology Fellowship Education Coordinator Contact Telephone 904-953-3386


103

http://ldft.huji.ac.il/fellowships-information/technion-fellowships/graduate-students




https://www.lupusresearch.org/research-and-clinical-trials/research/funding-opportunities/

https://www.lupusresearch.org/wp-content/uploads/2020/02/GTSA-RFA_FINAL3.pdf



https://college.mayo.edu/academics/residencies-and-fellowships/endocrinology-fellowship-florida/




Synopsis

Mayo Clinic in Florida offers a two-year, fully accredited Endocrinology Fellowship. Program highlights include: a broad curriculum encompassing all components of endocrinology, diabetes and metabolism; experience in treating metabolic disorders in patients undergoing solid organ transplant; Diverse elective opportunities; and clinical and laboratory research experience.

038045 Research Grants Ménière’s Society 15-Nov-2020 Not Specified

Contact Name Natasha Harrington-Benton Contact Telephone +44 0 1306 876883



Synopsis The Ménière’s Society’s Research Programme supports vital research into vestibular disorders.

061252 Merck MISP Diabetes Grant Merck 03-Nov-2020 Not Specified

Contact Name Jill Conner Contact Telephone 267-305- 2196



104

https://college.mayo.edu/academics/residencies-and-fellowships/endocrinology-fellowship-florida/application-process/



https://www.menieres.org.uk/research

https://www.menieres.org.uk/research/how-to-apply-for-a-research-grant



http://engagezone.msd.com/misp.html

http://engagezone.msd.com/diabetes.html



Synopsis

The Investigator Studies Program aims to advance science and improve patient care by supporting, through the provision of drug/vaccine and/or total/partial funding, high-quality research that is initiated, designed, implemented and sponsored by external investigators. Results will be generated and properly disseminated in peer-reviewed publications.

037398 Research Associateship Program (RAP) National Academies 01-Nov-2020 Not Specified




Synopsis The mission of the NRC Research Associateship Programs (RAP) is to promote excellence in scientific and technological research conducted by the U. S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions.

055113 Pioneer SCA3/MJD Translational Research Awards National Ataxia Foundation 05-Oct-2020 [LOI/Pre-App]

100,000 USD




105



http://sites.nationalacademies.org/

http://sites.nationalacademies.org/pga/rap/



https://ataxia.org/researcher-resources/#spnResearchGrants

https://secureservercdn.net/166.62.112.199/y1x.318.myftpupload.com/wp-content/uploads/2020/06/FY-2021-Pioneer-SCA-Translational-Research-Award-Instructions.pdf



Synopsis The Pioneer SCA3/MJD Translational Research Award is for a research project that will facilitate the development of treatments for Spinocerebellar Ataxia Type 3/Machado Joseph Disease. The total grant amount is $100,000.

001639 Research Associateship Programs -- Naval Medical Research Center/Naval Health Research Center (NMRC/NHRC) National Research Council 01-Nov-2020 Not

Specified





058602 Research Associateship Programs -- U.S. Army Medical Research and Materiel Command National Research Council 02-Nov-2020 Not

Specified

Contact Name Dr. Ray Gamble, Program Administrator Contact Telephone 202-334-2787



Synopsis The mission of the NRC Research Associateship Programs (RAP) is to promote excellence in scientific and technological research conducted by the U. S. government through the administration of programs offering graduate, postdoctoral,

106




https://sites.nationalacademies.org/pga/rap/

https://nrc58.nas.edu/RAPLab10/Opportunity/Program.aspx?LabCode=56&ReturnURL=%2fRAPLab10%2fOpportunity%2fPrograms.aspx%3fLabCode%3d56




https://sites.nationalacademies.org/PGA/RAP/index.htm

http://nrc58.nas.edu/RAPLab10/Opportunity/Program.aspx?LabCode=97&ReturnURL=%2fRAPLab10%2fOpportunity%2fPrograms.aspx%3fLabCode%3d97



and senior level research opportunities at sponsoring federal laboratories and affiliated institutions.

001613 Research Associateship Programs -- Federal Highway Administration (FHWA) National Research Council 01-Nov-2020 80,000 USD




Synopsis

The mission of the NRC Research Associateship Programs (RAP) is to promote excellence in scientific and technological research conducted by the U. S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions. Competitive awards are available for scientists and engineers to conduct independent research in federal laboratories and affiliated institutions. Awards include attractive stipends, health insurance, professional travel, and relocation.

058572 Research Associateship Programs -- Naval Postgraduate School National Research Council 02-Nov-2020 Not Specified

Contact Name Dr. Ray Gamble, Program Administrator Contact Telephone 202-334-2787



Synopsis The mission of the NRC Research Associateship Programs (RAP) is to promote excellence in scientific and technological

107



https://sites.nationalacademies.org/pga/rap/

https://nrc58.nas.edu/RAPLab10/Opportunity/Program.aspx?LabCode=27







research conducted by the U. S. government through the administration of programs offering graduate, postdoctoral, and senior level research opportunities at sponsoring federal laboratories and affiliated institutions.

058605 Research Associateship Programs -- U.S. Army Research Office National Research Council 02-Nov-2020 Not Specified

Contact Name Dr. Eric Basques, Program Administrator Contact Telephone 202-334-2707




058596 Research Associateship Programs -- U.S. Army Research, Development & Engineering Command, NVESD (RDEC/NVESD) National Research Council 02-Nov-2020 Not

Specified




Synopsis The mission of the NRC Research Associateship Programs (RAP) is to promote excellence in scientific and technological research conducted by the U. S. government through the administration of programs offering graduate, postdoctoral,

108












and senior level research opportunities at sponsoring federal laboratories and affiliated institutions.

058604 Research Associateship Programs -- U.S. Army Research Laboratory National Research Council 02-Nov-2020 Not Specified





058542 Research Associateship Programs -- Air Force Research Laboratory National Research Council 02-Nov-2020 80,000 USD

Contact Name Ms. Ellen M. Robinson Contact Telephone 703-588-8527



Synopsis Competitive awards are available for scientists and engineers to conduct independent research in federal laboratories and affiliated institutions. Awards include attractive stipends, health insurance, professional travel, and relocation.

001033 Research Associateship Programs -- Naval Research Laboratory National Research Council 01-Nov-2020 Not

109












Specified

Contact Name Ms. Erica Deschak Contact Telephone 202-767-8323



Synopsis The Naval Research Laboratory conducts a broad based multidisciplinary program of scientific research in advanced technological development, techniques, systems, and related operational procedures

018771 Department of Medicine - Physician-Scientist Training Program Northwestern University Feinberg School of Medicine 07-Nov-2020 4,000 USD

Contact Name Benjamin D. Singer, M.D. Contact Telephone 312-503-4494



Synopsis

The Department of Medicine’s Physician-Scientist Training Program at the Feinberg School of Medicine focuses on the transition period from graduation with an MD or combined MD/PhD degree to appointment to a full-time academic position as a physician-scientist. Beyond training in the Categorical Internal Medicine Training Program at the McGaw Medical Center of Northwestern University and the Northwestern University Feinberg School of Medicine, trainees accepted into the program will be guaranteed a position in the fellowship program of any of the 11 clinical divisions in the Department of Medicine and a minimum of $75,000 of support during clinical and research training.

110


http://sites.nationalacademies.org/PGA/RAP/index.htm



https://www.medicine.northwestern.edu/education/residents/residency-experience/pstp.html

https://www.feinberg.northwestern.edu/sites/physician-scientist/pstp-programming/medicine/index.html



018964 Department of Psychiatry & Behavioral Sciences - Psychiatry Residency Northwestern University Feinberg School of Medicine 30-Nov-2020 Not

Specified

Contact Name Mia Reed Contact Telephone 312-926-8058



Synopsis This four-year residency program in general psychiatry emphasizes in-depth understanding of the individual patient. Residents are well prepared for a wide range of psychiatric careers such as research, teaching and hospital-based or private practice. There are nine positions available in each class, including an R25-sponsored research track.

018855 Department of Orthopaedic Surgery - Residency Program Northwestern University Feinberg School of Medicine 01-Nov-2020 Not

Specified

Contact Name Latisha Emerson-Henderson Contact Telephone 312-472-6023



Synopsis

The five-year Northwestern University Feinberg School of Medicine’s Orthopaedic Surgery Residency Program broadens residents’ foundation in the basic sciences while providing exposure to clinical problems. Providing residents with the experience essential to the diagnosis and treatment of adult and pediatric musculoskeletal disorders allows them to develop into knowledgeable, compassionate, and ethical orthopaedic surgeons.

111



https://www.psychiatry.northwestern.edu/education/residents/index.html

https://www.psychiatry.northwestern.edu/education/residents/admissions.html



http://www.orthopaedics.northwestern.edu/education/residents/index.html

http://www.orthopaedics.northwestern.edu/education/residents/application-process.html



080227 Early Career Faculty Research Award Peripheral Vascular Surgery Society 06-Nov-2020 22,500

USD




Synopsis

The VESS Early Career Faculty Research Award is specifically designed to help new vascular surgical investigators initiate projects that will lead to extramural funding for basic or clinical research. One $22,500 grant for basic/translational science, educational, clinical or health outcomes research will be awarded during the VESS winter meeting.

010211 Franco-American Medical Exchanges Grants Philippe Foundation, Inc. 31-Aug-2020 Not Specified



Program URL Link to program URL Deadline Dates (ALL) 31-Aug-2020 , 30-Nov-2020

Synopsis The purpose of the Philippe Foundation is to encourage, assist, aid and support scientific and medical activities and research by giving grants to doctors and scientists (post-graduates) interested in exchange programs between France and the United States, specifically in medical laboratories.

112



http://vesurgery.org/

http://vesurgery.org/grants-awards/faculty-research



https://www.philippefoundation.org/

https://www.philippefoundation.org/home/application/



017925 College Travelling Fellowships Royal College of Physicians and Surgeons of Glasgow 30-Nov-2020 2,600 USD

Contact Name Contact Telephone +44 (0) 141 221 6072



Synopsis

The College awards up to 10 College Travelling Fellowships each year, to encourage the further education of younger Fellows and Members. These scholarships are intended to help our members travel to centres of excellence to gain invaluable experience. These awards will also support a variety of other learning opportunities including taster weeks for junior doctors.

017891 Ritchie Trust Research Fellowship Royal College of Physicians and Surgeons of Glasgow 30-Nov-2020 39,000

USD

Contact Name Shona McCall Contact Telephone +44 (0)141 221 6072



Synopsis A one-year Research Fellowship is funded by the Ritchie Trust. One fellowship of £30,000 is awarded every three years.

056819 Presidential Awards Sage (Russell) Foundation 19-Nov-2020 50,000

113



https://rcpsg.ac.uk/

https://rcpsg.ac.uk/awards-and-scholarships/college-travelling-fellowship



http://www.rcpsg.ac.uk/

https://rcpsg.ac.uk/college/career-support/awards-and-scholarships/research-awards/ritchie-trust-research-fellowship




USD




Synopsis

The Russell Sage Foundation (RSF) has long supported social science research with the aim of improving social and living conditions in the United States. In response to the crises of 2020, the foundation is dedicating its next funding cycle exclusively to research that seeks to improve our understanding of these extraordinary times. The severe consequences of the Covid19-pandemic, including its economic disruptions, and the recent mass protests to combat systemic racial inequality in policing and other institutions have reaffirmed the importance of social science research examining economic, political, racial, ethnic, generational, and social inequalities relevant to public policy and social change.

000548 Trustee (Research) Grants Sage (Russell) Foundation 19-Nov-2020 175,000 USD




Synopsis The Russell Sage Foundation makes external grants for social science research projects that address questions of interest under its core programs -- Behavioral Economics; Future of Work; Race, Ethnicity and Immigration; and Social,

114


https://www.russellsage.org/how-to-apply/project-presidential-awards

https://www.russellsage.org/how-to-apply/apply-project-grants/guidelines



http://www.russellsage.org/how-to-apply

http://www.russellsage.org/how-to-apply/project-presidential-awards



Political and Economic Inequality -- along with other special initiatives. ADDENDUM: Because of the effects of COVID-19 on all facets of American life, the Russell Sage Foundation is changing its immediate priorities for letters of inquiry for the May 21, 2020, deadline. For this deadline, RSF will only consider LOIs that satisfy at least one of the following criteria: The research is so timely and time-sensitive that the project must start before April 1, 2021; or the research analyzes social, political, economic, or psychological disruptions resulting from the coronavirus crisis that affect social and living conditions in the United States.

039020 Community Relations Contributions Sanofi Genzyme Corporation 15-Nov-2020 Not Specified

Contact Name Kristen Brown, Associate Manager, Community Relations Contact Telephone 617-685-5059



Synopsis Sanofi Genzyme provides Community Relations Grants to support non-profit organizations focused on science education, health/access to health care, and unmet community needs, specifically in and around the areas in the U.S. where Genzyme has a business presence.

095808 Fellowship Grants Sarepta Therapeutics 15-Nov-2020 Not Specified




115



https://www.sanofigenzyme.com/Responsibility/Contributions-and-Giving.aspx

https://www.sanofigenzyme.com/responsibility/contributions-and-giving/submit-an-application-online



https://www.sarepta.com/

https://www.sarepta.com/about-us/grants-giving#paragraph-3946




Synopsis The sponsor is committed to developing precision genetic medicines aimed to improve and extend the lives of patients with rare genetic-based diseases. Their funding opportunities aim to provide support to those who will be working urgently in this fight.

026756 Research Grant Spine Intervention Society 01-Nov-2020 Not Specified




Synopsis The Spine Intervention Society (SIS) is proud to provide funding for high quality research to help generate definitive evidence and support the spine intervention field.


Amount

067234 SPRC Research Fellowship Program in Cardiovascular Disease Prevention Stanford University 15-Nov-2020 Not Specified

Contact Name Christopher D. Gardner, PhD, Training Program Director Contact Telephone 650-723-1334


116



https://www.spineintervention.org/

https://www.spineintervention.org/page/R1_RF




https://prevention.stanford.edu/education/fellowship.html




Synopsis

The SPRC Research Fellowship Program in Cardiovascular Disease Prevention is intended for early career training, it does not include clinical training and specifically is not a cardiology subspecialty program. The training program is fully integrated into the Stanford Prevention Research Center and is governed by the Center faculty and academic research staff. The three major elements of the training program are: direct research experience; directed study and data analysis; and, a core seminar program.

091400 Early Career Awards Thrasher Research Fund 15-Sep-2020 [LOI/Pre-App] 25,000 USD




Synopsis

The Fund recognizes that young investigators may find it difficult to remain in pediatric research because of a lack of funding. Therefore, the purpose of this program is to encourage the development of medical research in child health by awarding small grants to new researchers, helping them gain a foothold in this important area. The goal is to fund applicants who will go on to be independent investigators. The Fund will make up to 30 awards total with two funding cycles (15 awards each).

096088 Training TRANSVAC 15-Nov-2020 Not Specified

Contact Name Contact Telephone 0049 17660863372


117

https://prevention.stanford.edu/education/fellowship/criteria.html


https://www.thrasherresearch.org/

https://www.thrasherresearch.org/early-career-award?lang=eng







Synopsis Training scientists in vaccine research and development is crucial in order to sustain Europe’s excellence in this field. The TRANSVAC2 Consortium has set up training modules at leading European centres (in collaboration with WP18 partners) that can be combined to create customised international courses on vaccine R&D.

026902 Pilot Research Program Tulane National Primate Research Center 01-Nov-2020 60,000 USD

Contact Name Pyone Pyone Aye DVM, PhD Contact Telephone 985-871-6486


Program URL Deadline Dates (ALL) 01-Nov-2020

Synopsis

The purpose of the Pilot Research Program is to provide funds to investigators who show promise of developing a strong career in nonhuman primate biomedical research or who wish to add a nonhuman primate component to their existing research programs. The program is also open to investigators with established research programs using nonhuman primates who wish to develop substantially new research directions.

017842 Regular Research Grants Program United States - Israel Binational Science Foundation 18-Nov-2020 250,000 USD



118

https://www.transvac.org/

https://www.transvac.org/training



https://tnprc.tulane.edu/pilot-research-program







Synopsis The United States - Israel Binational Science Foundation (BSF) Research Grants program is the main program of the BSF, and it funds both U.S. and Israeli scientists who wish to work together.

059983 Early Career Faculty Research Award Vascular and Endovascular Surgery Society 06-Nov-2020 22,500 USD




Synopsis

The VESS Early Career Faculty Research Award is specifically designed to help new vascular surgical investigators initiate projects that will lead to extramural funding for basic or clinical research. One $22,500 grant for basic/translational science, educational, clinical or health outcomes research will be awarded during the VESS winter meeting.

090465 Individual Research Grant Wings for Life Spinal Cord Research Foundation 01-Sep-2020

[LOI/Pre-App] Not Specified

Contact Name Dr. Verena May Contact Telephone +43 (0)662 6582-4246


119

http://www.bsf.org.il/

http://www.bsf.org.il/funding-opportunities/bsf-research-grants/about/



https://vesurgery.org/grants-awards/

https://vesurgery.org/grants-awards/early-career-faculty/



http://www.wingsforlife.com/




Synopsis

Wings for Life is a non-profit research organization with the exclusive aim to support basic and clinical research related to spinal cord injury. Research projects may address all aspects of spinal cord lesions, nerve regeneration, trophic support of injured neurons and functional changes induced by lesions (preferentially in mammals). Individual grants are intended only to cover the salary of the applicant: Post-docs, PhDs, and/or technicians.

090466 Project Grants Wings for Life Spinal Cord Research Foundation 01-Sep-2020

[LOI/Pre-App] 351,000 USD

Contact Name Dr. Verena May Contact Telephone +43 (0)662 6582-4246



Synopsis

Wings for Life is a non-profit research organization with the exclusive aim to support basic and clinical research related to spinal cord injury. Research projects may address all aspects of spinal cord lesions, nerve regeneration, trophic support of injured neurons and functional changes induced by lesions (preferentially in mammals). Project research grants are is intended to sustain a full research project. Funds cover personnel, equipment, consumables, etc.

120

http://www.wingsforlife.com/us/latest/grant-application-2079/



https://www.wingsforlife.com/us/research/#key-areas

https://www.wingsforlife.com/us/latest/grant-application-2079/

icahn.mssm.edu · 2020. 8. 24. · fogarty international center/nih/dhhs par-19-038 04-nov-2020...

Documents